Devices and methods for delivering therapeutics
Patent Information
- Application Number
- JP2024103857
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2017-06-14
- Filing Date
- 2024-06-27
- Publication Date
- 2024-12-03
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
Existing insulin delivery devices for diabetes management are bulky and cumbersome, and implantable devices face challenges in allowing high flux of low molecular weight therapeutic agents while preventing the passage of larger proteins or cells.
A device comprising a membrane with non-native pancreatic beta cells that exhibit glucose-stimulated insulin secretion, encapsulating cells or therapeutic agents, and a membrane designed to allow differential diffusion coefficients for molecules based on molecular weight, restricting passage of larger entities while allowing release of therapeutic agents.
The device enables long-term, unobtrusive insulin delivery with high flux of low molecular weight therapeutic agents while preventing infiltration of host proteins or cells, providing effective treatment for chronic diseases like diabetes.
Abstract
Description
[Technical field]
[0001] cross reference
[0001] This application claims the benefit of U.S. Provisional Application No. 62 / 519,702, filed June 14, 2017, which is incorporated by reference in its entirety into this specification. [Background technology]
[0002]
[0002] Diabetes is a chronic disease that affects the quality of life of patients. Therapeutic devices to assist in the automatic delivery of insulin can be bulky and cumbersome for patients to use. Implantable devices can offer advantages because they can be unobtrusive and easy to manage. Implantable devices can benefit from exhibiting long-term structural integrity and can benefit from allowing the passage of therapeutic agents without allowing the infiltration of host proteins. The present invention provides devices and methods of administering the same that allow high flux of low molecular weight therapeutic moieties while limiting the passage of larger proteins or cells. Summary of the Invention
[0003] SUMMARY OF THE DISCLOSURE
[0003] Disclosed herein are devices, methods and compositions for delivering therapeutic agents (eg, cells or therapeutic agents).
[0004] In one aspect, a device is disclosed that includes a membrane and a population of non-native pancreatic beta cells, wherein said non-native pancreatic beta cells exhibit an in vitro glucose stimulated insulin secretion (GSIS) response to a glucose load, wherein said membrane has a GSIS of about 2 or more.
[0004] [ka]
[0005] Ratio, where D first is the first diffusion coefficient for the first molecule having the first molecular weight, D secondis a second diffusion coefficient for a second molecule having a second molecular weight, and wherein the ratio of the second molecular weight to the first molecular weight is about 10 or greater.
[0006] In some cases, the non-native pancreatic beta cells are encapsulated within the device. In some cases, the non-native pancreatic beta cells do not express somatostatin, glucagon, or both. In some cases, the device is designed to produce and release insulin when implanted into a subject. In some cases, the non-native pancreatic beta cells are encapsulated within the device ... 4 ~about 10 6 In some cases, the membrane is designed to block the passage of the non-native pancreatic β cells.
[0007]
[0006] In another aspect, a device is disclosed comprising a membrane and a population of cells, wherein at least one cell of the population of cells produces a first molecule comprising a first molecular weight and at least one cell of the population of cells produces a second molecule comprising a second molecular weight, wherein the device is designed, when implanted into a subject, to release the first molecule at a first flux rate and release the second molecule at a second flux rate, wherein the first flux rate is different from the second flux rate and wherein the ratio of the first molecular weight to the second molecular weight is from about 1.0 to about 5.0.
[0008] In some cases, the first molecule or the second molecule includes a therapeutic agent. In some cases, the first molecule is insulin. In some cases, the second molecule is glucagon. In some cases, the ratio of the first molecular weight to the second molecular weight is about 1.6. In some cases, the second molecule is somatostatin. In some cases, the ratio of the first molecular weight to the second molecular weight is about 3.5. In some cases, the therapeutic agent is a hormone or an enzyme. In some cases, the therapeutic agent is a hormone. In some cases, the therapeutic agent is an amino acid-derived hormone, an eicosanoid, a peptide hormone, or a steroid. In some cases, the therapeutic agent is selected from the group consisting of glucagon, growth hormone, insulin, pancreatic polypeptide, parathyroid hormone, somatostatin, and glucocorticoid. In some cases, the therapeutic agent is an enzyme. In some cases, the therapeutic agent is a protease, lipase, amylase, phospholipase A2, lysophospholipase, or cholesterol esterase. In some cases, the therapeutic agent is selected from the group consisting of angiotensinogen, trypsinogen, chymotrypsinogen, pepsinogen, fibrinogen, procaspase, pacifastin, proelastase, prolipase, and procarboxypolypeptidase. In some cases, the cells include hormone- or enzyme-secreting cells. In some cases, the cells include non-native cells. In some cases, the cells include stem cell-derived islet cells. In some cases, the cells include non-native pancreatic β cells. In some cases, the cells exhibit an in vitro glucose-stimulated insulin secretion (GSIS) response to a glucose load. In some cases, the cells are encapsulated within the device. In some cases, the cells do not express somatostatin, glucagon, or both. In some cases, the device is designed to produce and release insulin when implanted into the subject. In some cases, the cells are at about 10 per μL of volume. 4 ~about 10 6Within the cell are encapsulated within the device. In some cases, the membrane is designed to block the passage of the cells.
[0009]
[0008] In another aspect, a device is disclosed that includes a membrane and a therapeutic agent, wherein said therapeutic agent is encapsulated within said device, and wherein said membrane has a molecular weight of about 2 or more.
[0010] [ka]
[0011] Ratio, where D first is the first diffusion coefficient for the first molecule having the first molecular weight, D second is a second diffusion coefficient for a second molecule comprising a second molecular weight, and wherein the ratio of said second molecular weight to said first molecular weight is greater than or equal to about 10.
[0012] In some cases, the therapeutic agent is a prodrug. In some cases, the therapeutic agent is less than 10 kDa. In some cases, the therapeutic agent is a small molecule. In some cases, the therapeutic agent is a biological agent. In some cases, the biological agent is a peptide or protein. In some cases, the therapeutic agent is a hormone or enzyme. In some cases, the therapeutic agent is a hormone. In some cases, the therapeutic agent is an amino acid derived hormone, an eicosanoid, a peptide hormone, or a steroid. In some cases, the therapeutic agent is selected from the group consisting of glucagon, growth hormone, insulin, pancreatic polypeptide, parathyroid hormone, somatostatin, and glucocorticoid. In some cases, the therapeutic agent is an enzyme. In some cases, the therapeutic agent is a protease, lipase, amylase, phospholipase A2, lysophospholipase, or cholesterol esterase. In some cases, the therapeutic agent is selected from the group consisting of angiotensinogen, trypsinogen, chymotrypsinogen, pepsinogen, fibrinogen, In some cases, the therapeutic agent is selected from the group consisting of ribonuclease, procaspase, pacifastin, proelastase, prolipase, and procarboxypolypeptidase. In some cases, the therapeutic agent is present in a range of about 0.01 mg therapeutic agent / mg polymer to about 0.5 mg therapeutic agent / mg polymer. In some cases, the therapeutic agent is designed to be released from the membrane for at least 3 days. In some cases, the therapeutic agent is hydrophobic. In some cases, the therapeutic agent is hydrophilic. In some cases, the therapeutic agent is in the form of finely divided particles.
[0013]
[0010] In another aspect, a device is disclosed that includes a membrane, wherein said membrane comprises a polymer designed to allow encapsulation of a population of cells or a therapeutic agent, wherein said membrane comprises at least one of the following: a) an average fiber diameter of about 1000 nm or less; b) an average pore size of about 5 μm or less; and c) an average thickness of about 500 μm or less; and wherein said membrane has a pore size of about 2 or more.
[0014] [ka]
[0015] Ratio, where D first is the first diffusion coefficient for the first molecule having the first molecular weight, D second is a second diffusion coefficient for a second molecule having a second molecular weight, and wherein the ratio of the second molecular weight to the first molecular weight is about 10 or greater.
[0016] In some cases, the polymer is designed to allow encapsulation of the cell population. In some cases, the cells include hormone or enzyme secreting cells. In some cases, the cells secrete a therapeutic agent. In some cases, the therapeutic agent is a hormone. In some cases, the therapeutic agent is an amino acid derived hormone, an eicosanoid, a peptide hormone or a steroid. In some cases, the therapeutic agent is selected from the group consisting of glucagon, growth hormone, insulin, pancreatic polypeptide, parathyroid hormone, somatostatin and glucocorticoids. In some cases, the therapeutic agent is an enzyme. In some cases, the therapeutic agent is a protease, lipase, amylase, phospholipase A2, lysophospholipase or cholesterol esterase. In some cases, the therapeutic agent is selected from the group consisting of angiotensinogen, trypsinogen, chymotrypsinogen, pepsinogen, fibrinogen, procaspase, pacifastin, proelastase, prolipase, and procarboxypolypeptidase. In some cases, the cells include non-native cells. In some cases, the cells include stem cell-derived pancreatic islet cells. In some cases, the cells include non-native pancreatic β cells. In some cases, the cells exhibit an in vitro glucose-stimulated insulin secretion (GSIS) response to a glucose load. In some cases, the cells are encapsulated within the device. In some cases, the cells do not express somatostatin, glucagon, or both. In some cases, the device is designed to produce and release insulin when implanted into the subject. In some cases, the cells are present in a concentration of about 10 per μL of volume. 4 ~about 10 6 Within the cell are encapsulated within the device. In some cases, the membrane is designed to block the passage of the cells.
[0017] In some cases, the polymer is designed to allow for encapsulation of the therapeutic agent. In some cases, the therapeutic agent is a prodrug. In some cases, the therapeutic agent is less than 10 kDa. In some cases, the therapeutic agent is a small molecule. In some cases, the therapeutic agent is a biological agent. In some cases, the biological agent is a peptide or protein. In some cases, the therapeutic agent is a hormone or is an enzyme. In some cases, the therapeutic agent is a hormone. In some cases, the therapeutic agent is an amino acid-derived hormone, an eicosanoid, a peptide hormone, or a steroid. In some cases, the therapeutic agent is selected from the group consisting of glucagon, growth hormone, insulin, pancreatic polypeptide, parathyroid hormone, somatostatin, and glucocorticoids. In some cases, the therapeutic agent is an enzyme. In some cases, the therapeutic agent is a protease, lipase, amylase, phospholipase A2, lysophospholipase, or cholesterol esterase. In some cases, the therapeutic agent is selected from the group consisting of angiotensinogen, trypsinogen, chymotrypsinogen, pepsinogen, fibrinogen, procaspase, pacifastin, proelastase, prolipase, and procarboxypolypeptidase. In some cases, the therapeutic agent is present in a range of about 0.01 mg therapeutic agent / mg polymer to about 0.5 mg therapeutic agent / mg polymer. In some cases, the therapeutic agent is designed to be released from the membrane for at least three days. In some cases, the therapeutic agent is hydrophobic. In some cases, the therapeutic agent is hydrophilic. In some cases, the therapeutic agent is in the form of finely divided particles.
[0018]
[0013] In some cases, the membrane comprises an average fiber diameter of about 1000 nm or less. In some cases, the average fiber diameter is about 800 nm or less. In some cases, the average fiber diameter is about 500 nm or less. In some cases, the membrane comprises an average pore size of about 5 μm or less. In some cases, the average pore size is about 2 μm or less. In some cases, the average pore size is about 1 μm or less. In some cases, the membrane comprises an average thickness of about 800 μm or less. In some cases, the average thickness is about 500 μm or less. In some cases, the average thickness is about 200 μm or less. In some cases, the first molecular weight is less than about 10 kDa and the second molecular weight is greater than about 100 kDa. In some cases, the first molecular weight is about 4 kDa and the second molecular weight is about 150 kDa. In some cases, the first molecule is a 4 kDa FITC-dextran molecule and the second molecule is a 500 kDa FITC-dextran molecule. In some cases, the membrane is an electrospun polymer membrane. In some cases, the membrane further comprises a base polymer. In some cases, the base polymer comprises PAN, PET, PLG, PHEMA, PCL, or PLLA. In some cases, the base polymer is PAN. In some cases, the membrane further comprises a functional polymer. In some cases, the functional polymer comprises PEG, PEGMA, PEGDA, or TEGDA. In some cases, the functional polymer is PEGMA. In some cases, the functional polymer is TEGDA. In some cases, the functional polymer comprises a reactive functional group. In some cases, the reactive functional group is a carboxylate group, a hydroxyl group, an amide group, an azide group, or a maleimide group. In some cases, the functional polymer comprises a molecular weight in the range of about 400 to 4000 Da. In some cases, the functional polymer comprises a molecular weight of about 480 Da. In some cases, the functional polymer comprises a molecular weight in the range of about 1500-2500 Da. In some cases, the functional polymer comprises a molecular weight of about 2000 Da. In some cases, the ratio is about 3 or more. In some cases, the ratio is about 5 or more. In some cases, the ratio is about 10 or more.In some cases, the membrane comprises a tensile strength of about 1 MPa or greater. In some cases, the membrane comprises a Young's modulus of about 5 MPa or greater. In some cases, the membrane is hydrophilic. In some cases, the membrane is hydrophobic.
[0019]
[0014] In another aspect, a method of treating a condition is disclosed that includes placing any of the devices disclosed herein in a subject in need thereof. In some cases, the device is designed to remain in the subject for a period of time greater than six months. In some cases, the condition is a chronic disease. In some cases, the chronic disease is diabetes. In some cases, the condition is a tissue wound. In some cases, the condition is a vascular endothelial cell. The condition is hypoparathyroidism. In some cases, the method further comprises monitoring the subject's insulin levels over the period of greater than six months.
[0020]
[0015] In another aspect, a method of making a device for delivering a population of cells or a therapeutic agent to a subject in need thereof is disclosed, the method comprising: dissolving a polymer in a solvent to provide a polymer solution; using the polymer solution to form a membrane comprising fibers; and assembling the membrane into the device, wherein the device is any device disclosed herein.
[0021] In some cases, the method further comprises crosslinking the film. In some cases, crosslinking the film comprises exposing the film to ultraviolet (UV) light in the presence of a photoinitiator. In some cases, the photoinitiator is acetophenone, anisoin, anthraquinone, benzil, benzoin, benzenetricarbonylchromium, benzoin ethyl ether, benzoin isobutyl ether, benzoin methyl ether, benzophenone, 3,3',4,4'-benzophenonetetracarboxylic dianhydride, 4-benzoylbiphenyl, 2-benzyl-2-(dimethylamino)-4'-morpholinobutyrophenone, 4,4'-bis(diethylamino)benzophenone, camphorquinone, 2-chlorothioxanthen-9-one, (cumene)cyclopentadienyliron(II) hexafluorophosphate, dibenzosuberenone, 2,2-diethoxyacetophenone, 4,4'-dihydroxybenzophenone, 2,2-dimethoxy-2-phenylacetophenone, 4-(dimethylamino)benzophenone, 4,4'-dimethylbenzyl, 2,5-dimethylbenzophenone, zonphenone, 3,4-dimethylbenzophenone, diphenyl(2,4,6-trimethylbenzoyl)phosphine oxide, 4'-ethoxyacetophenone, 2-ethylanthraquinone, ferrocene, 3-hydroxyacetophenone, 4-hydroxyacetophenone, 1-hydroxycyclohexyl phenyl ketone, 2-hydroxy-2-methylpropiophenone, 2-methylbenzophenone, 3-methylbenzophenone, methylbenzoyl formate, 2-methyl-4'-(methylthio)-2-morpholinopropiophenone, phenanthrenequinone, 4'-phenoxyacetophenone, thioxanthen-9-one, triarylsulfonium, hexafluoroantimonate salts, triarylsulfonium hexafluorophosphate salts, or any combination thereof. In some cases, crosslinking the film includes exposing the film to heat in the presence of a thermal initiator.In some cases, the thermal initiator is selected from the group consisting of ammonium persulfate, tert-amyl peroxybenzoate, 4,4-azobis(4-cyanovaleric acid), 1,1'-azobis(cyclohexanecarbonitrile), 2,2'-azobisisobutyronitrile, benzoyl peroxide, 2,2'-bis(tert-butylperoxy)butane, 1,1-bis(tert-butylperoxy)cyclohexane, 2,5-bis(tert-butylperoxy)-2,5-dimethylhexane, 2,5-bis(tert-butylperoxy)-2,5-dimethyl-3-hexane, and the like. In some cases, the crosslinking agent may be selected from the group consisting of dimethyl ether, ... In this case, the crosslinking agent is tetra(ethylene glycol) diacrylate, polyethylene glycol diacrylate, diacralte), bis(2-(succinimidyl-oxycarbonyloxyl)ethyl)sulfone, di(n-succinimidyl)glutarate, disuccinimidyl tartrate, 3,3'-dithiobis(sulfosuccinimidyl)propionate, p-phenylenediisothiocyanate, sebacic acid bis(N-succinimidyl)ester, suberic acid bis(N-hydroxysuccinimide ester), APN-CHO, bromoacetic acid N-hydroxysuccinimide ester, CBTF, iodoacetic acid N-hydroxysuccinimide ester, maleimido-PEG-succinimidyl ester, maleimido-acetic acid N-hydroxysuccinimide ester, adipic acid dihydrazide, alkyne-PEG-maleimide, APN-amine, APN-azide, APN-BCN, APN-COCl, biotin-benzyl-tetrate radish, biotin-PEG-TPG, 1,11-diazido-3,6,9-trioxaundecane, dibenzocyclooctyne-N-hydroxysuccinimidyl ester, dibenzocyclooctyne-maleimide, dibenzocyclooctyne-PEG-maleimide, 4-(maleimido)phenylisocyanate (approximately 95% pure), 4,4'-methylenebis(phenylisocyanate), 3-(2-pyridyldithio)propionylhydrazide, propargyl-N-hydroxylsuccinimidyl ester, PTAD-azide, sulfo-NHS-diazirine, sulfosuccinimidyl 4,4'-azipentanoate, 4-(N-maleimido)benzophenone, 4-azidophenacyl bromide, 5-azido-2-nitrobenzoic acid N-hydroxysuccinimidyl ester acid N-hydroxy succinimide ester), succinimidyl-[4-(psoralen-8-yloxy)]butyrate, 4-benzoylbenzoic acid N-succinimidyl ester, 1,4-bis[3-(2-pyridyldithio)propionamido]butane, bis-maleimidoethane, dithio-bis-maleimidoethane, or any combination thereof.
[0022]
[0017] In some cases, the method further comprises adding a drug to the polymer solution. In some cases, the solvent is a miscible solvent. In some cases, the drug is a hydrophobic drug. In some cases, the drug is a hydrophilic drug. In some cases, the drug is in the form of finely divided particles. In some cases, the method further comprises encapsulating cells within the device. In some cases, the cells are non-native cells. In some cases, the cells are stem cell-derived pancreatic islet cells. In some cases, the cells exhibit an in vitro glucose-stimulated insulin secretion (GSIS) response to a glucose load. In some cases, the method further comprises collecting the fibers using a rotating drum collector. In some cases, the method further comprises collecting the fibers on a patterned structure. In some cases, the membrane comprises the shape of the patterned structure. In some cases, the solvent includes DMF, acetone, acetonitrile, aniline, n-butyl acetate, cyclohexanone, chloroform, diacetone alcohol, di(ethylene glycol), dimethyl sulfoxide, dichloromethane, ethanol, ethyl acetate, ethylene dichloride, formic acid, glycerol, methanol, methyl acetate, morpholine, 2-nitropropane, 1-pentanol, n-propanol, pyridine, trifloroethanol, tetrahydrofuran, water, or any combination thereof. In some cases, dissolving the polymer in the solvent includes dissolving a base polymer and a functional polymer in the solvent. In some cases, dissolving the base polymer and the functional polymer in a ratio of about 1:1 (w / w) or less in the solvent. In some cases, the base polymer and the functional polymer are in a ratio of about 1:5 (w / w) or less in the solvent. In some cases, the base polymer and the functional polymer are in a ratio of about 1:10 (w / w) or less in the solvent. In some cases, the base polymer and the functional polymer are in a ratio of about 1:20 (w / w) or less in the solvent. The base polymer and the functional polymer are present with the solvent in about 6 weight to volume percent. In some cases, the membrane does not include a coating.
[0023] In various aspects, the present disclosure provides compositions for delivering cells or a therapeutic agent to a user, the compositions comprising a membrane (e.g., an electrospun polymer), where the membrane comprises a functional polymer designed to enable (1) crosslinking of the membrane and / or (2) conjugation of a therapeutic agent to the membrane, where the membrane has a molecular weight of about 2 or more.
[0024] [ka]
[0025] Ratio, where D first is the first diffusion coefficient for the moiety containing the first molecular weight, and D second is a second diffusion coefficient for the moiety comprising the second molecular weight, and wherein the ratio of the second molecular weight to the first molecular weight is about 10 or greater. In one aspect, the composition further comprises cells encapsulated within the device comprising the membrane. In one aspect, the cells are engineered to produce insulin. In a further aspect, the cells are engineered stem cell-derived beta cells. In yet another aspect, the engineered stem cells express insulin.
[0026] In a further aspect, the engineered stem cells are designed to secrete insulin immediately after encapsulation. In one aspect, the cells are at about 10 per μL of volume. 4 ~about 10 6 The cell is encapsulated within the device. In some aspects, the composition further comprises a drug. In some aspects, the drug is a prodrug. In a further aspect, the drug is less than 10 kDa. In some aspects, the drug is a small molecule. In other aspects, the drug is a biological agent. In a further aspect, the biological agent is a peptide or a protein.
[0027]
[0020] In some aspects, the drug is present in a range of about 0.01 mg drug / mg polymer to about 0.5 mg drug / mg polymer. In some aspects, the drug is designed to be released from the membrane for at least 3 days. In some aspects, the drug is a hydrophobic drug. In some aspects, the drug is contained in the fibers of the membrane (e.g., an electrospun polymer membrane). In some aspects, the drug is a hydrophilic drug. In some aspects, the drug is in the form of finely divided microparticles. In further aspects, the drug is dispersed within the membrane (e.g., an electrospun polymer membrane). In some aspects, the ratio of the second molecular weight to the first molecular weight is about 20 or greater.
[0028] In other aspects, the ratio of the second molecular weight to the first molecular weight is greater than or equal to about 30. In some aspects, the first molecular weight is less than about 10 kDa and the second molecular weight is greater than about 100 kDa. In further aspects, the first molecular weight is equal to about 4 kDa and the second molecular weight is equal to about 150 kDa.
[0029] In some aspects, the composition further comprises an antioxidant, a macrophage inhibitor, or an anti-inflammatory agent. In some aspects, the membrane is designed to allow the passage of cells. In further aspects, the membrane has a pore size of about 5 μm or more.
[0030] In other aspects, the membrane is designed to block the passage of cells. In further aspects, the membrane has a pore size of about 3 μm or less. In some aspects, the membrane does not include a coating. In some aspects, the base polymer is PAN, PET, PLG, In one aspect, the functional polymer comprises PEG, PEGMA, PEGDA, or TEGDA. In a further aspect, the base polymer is PAN. In yet another aspect, the functional polymer is PEGMA. In another aspect, the functional polymer is PEGDA. In yet another aspect, the functional polymer is TEGDA.
[0031]
[0024] In one aspect, the functional polymer comprises a reactive functional group. In one aspect, the reactive functional group is a carboxylate group, a hydroxyl group, an amide group, an azide group, or a maleimide group. In one aspect, the composition further comprises an anti-fibrotic agent, an anti-inflammatory agent, a pro-angiogenic agent, or a hydrophilizing agent. In one aspect, the functional polymer comprises a molecular weight in the range of about 400-4000 Da. In a further aspect, the functional polymer comprises a molecular weight in the range of about 1500-2500 Da.
[0032] In one aspect, the functional polymer comprises a molecular weight of about 2000 Da. In one aspect, the functional polymer comprises a molecular weight of about 480 Da. first is 10 -7 cm 2 In a further aspect, D first corresponds to the diffusion coefficient for insulin, and D second corresponds to the diffusion coefficient for IgG.
[0033]
[0026] In one aspect, the membrane comprises a tensile strength of about 1 MPa or greater. In one aspect, the membrane comprises a Young's modulus of about 5 MPa or greater. In one aspect, the membrane comprises fibers. In a further aspect, the fibers include a diameter in the range of about 180-240 nm. In another aspect, the fibers include a diameter in the range of about 520-560 nm. In one aspect, the fibers include a diameter of about 1000 nm or less. In one aspect, the membrane includes a thickness in the range of about 10-150 μm. In a further aspect, the membrane includes a thickness in the range of about 80-120 μm.
[0034]
[0028] In one aspect, the membrane comprises a base polymer and a functional polymer in a ratio of about 1:1. In another aspect, the membrane comprises a base polymer and a functional polymer in a ratio of about 1:5. In yet another aspect, the membrane comprises a base polymer and a functional polymer in a ratio of about 1:10. In yet another aspect, the membrane comprises a base polymer and a functional polymer in a ratio of about 1:20. In one aspect, the membrane is hydrophilic. In one aspect, the base polymer is designed to provide structural integrity to the membrane. In one aspect, the base polymer is hydrophobic.
[0035] In various aspects, the present disclosure provides a method of providing a composition disclosed herein for a therapy session comprising placing a membrane on a user, where the membrane is designed to remain on the user for a period of time greater than six months. In one aspect, the user has a chronic disease. In a further aspect, the chronic disease is diabetes. In one aspect, the method further comprises monitoring the insulin levels of the user for a period of time greater than six months.
[0036]
[0030] In various aspects, the present disclosure provides a method of providing a membrane for delivering cells or a therapeutic agent to a user, the method including dissolving a base polymer and a functional polymer designed to enable (1) crosslinking of the membrane and / or (2) conjugation of a therapeutic agent to the membrane in a solvent to provide a copolymer solution; electrospinning the copolymer solution to produce fibers; and collecting the fibers to form a membrane, wherein the membrane has a molecular weight of about 2 or more.
[0037] [ka]
[0038] Ratio, where D first is the diffusion coefficient for the portion containing the first molecular weight, and D secondis the diffusion coefficient for a moiety comprising a second molecular weight, where the ratio of the second molecular weight to the first molecular weight is greater than about 10.
[0039] In one aspect, the method further comprises crosslinking the membrane, wherein the crosslinking step comprises about 2 or more
[0040] [ka]
[0041] In one aspect, crosslinking the film comprises exposing the film to ultraviolet (UV) light in the presence of a photoinitiator. In a further aspect, the photoinitiator is selected from the group consisting of acetophenone, anisoin, anthraquinone, benzil, benzoin, benzenetricarbonylchromium, benzoin ethyl ether, benzoin isobutyl ether, benzoin methyl ether, benzophenone, 3,3',4,4'-benzophenonetetracarboxylic dianhydride, 4-benzoylbiphenyl, 2-benzyl-2-(dimethylamino)-4'-morpholinobutyrophenone, 4,4'-bis(diethylamino)benzophenone, camphorquinone, 2-chlorothioxanthen-9-one, (cumene)cyclopentadienyliron(II) hexafluorophosphate, dibenzosuberenone, 2,2-diethoxyacetophenone, 4,4'-dihydroxybenzophenone, 2,2-dimethoxy-2-phenylacetophenone, 4-(dimethylamino)benzophenone, 4,4'-dimethylbenzyl, 2,5-dimethylbenzophenone (2,5-dimethylbenzyl). benzophenone, 3,4-dimethylbenzophenone, diphenyl(2,4,6-trimethylbenzoyl)phosphine oxide, 4'-ethoxyacetophenone, 2-ethylanthraquinone, ferrocene, 3-hydroxyacetophenone, 4-hydroxyacetophenone, 1-hydroxycyclohexyl phenyl ketone, 2-hydroxy-2-methylpropiophenone, 2-methylbenzophenone, 3-methylbenzophenone, methylbenzoyl formate, 2-methyl-4'-(methylthio)-2-morpholinopropiophenone, phenanthrenequinone, 4'-phenoxyacetophenone, thioxanthen-9-one, triarylsulfonium, hexafluoroantimonate salts, triarylsulfonium hexafluorophosphate salts, or any combination thereof.
[0042] In one aspect, crosslinking the membrane comprises exposing the membrane to ultraviolet (UV) light in the presence of a photoinitiator and a crosslinking agent. In a further aspect, the crosslinking agent is selected from the group consisting of tetra(ethylene glycol) diacrylate, polyethylene glycol diacrylate, bis(2-(succinimidyl-oxycarbonyloxyl)ethyl)sulfone, di(n-succinimidyl)glutarate, disuccinimidyl tartrate, 3,3'-dithiobis(sulfosuccinimidyl)propionate, p-phenylenediisothiocyanate, sebacic acid bis(N-succinimidyl)ester, suberic acid bis(N-hydroxysuccinimide ester), APN-CHO, bromoacetic acid N-hydroxysuccinimide ester, CBTF, iodoacetic acid N-hydroxysuccinimide ester, maleimide-PEG-succinimidyl ester, PEG-succinimide ... ter, maleimidoacetic acid N-hydroxysuccinimide ester, adipic dihydrazide, alkyne-PEG-maleimide, APN-amine, APN-azide, APN-BCN, APN-COCl, biotin-benzyl-tetrazine, biotin-PEG-TPG, 1,11-diazido-3,6,9-trioxaundecane, dibenzocyclooctyne-N-hydroxysuccinimidyl ester, dibenzocyclooctyne-maleimide, dibenzocyclooctyne-PEG-maleimide, 4-(maleimido)phenyliso cyanate (approximately 95% pure), 4,4'-methylenebis(phenylisocyanate), 3-(2-pyridyldithio)propionylhydrazide, propargyl-N-hydroxylsuccinimidyl ester, PTAD-azide, sulfo-NHS-diazirine, sulfosuccinimidyl 4,4'-azipentanoate, 4-(N-maleimido)benzophenone, 4-azidophenacyl bromide, 5-azido-2-nitrobenzoic acid N-hydroxysuccinimide ester acid N-hydroxy succinimide ester), succinimidyl-[4-(psoralen-8-yloxy)]butyrate, 4-benzoylbenzoic acid N-succinimidyl ester, 1,4-bis[3-(2-pyridyldithio)propionamido]butane, bis-maleimidoethane, dithio-bis-maleimidoethane, or any combination thereof.
[0043] In one aspect, crosslinking the membrane comprises exposing the membrane to heat in the presence of a thermal initiator. In a further aspect, the thermal initiator is selected from the group consisting of ammonium persulfate, tert-amyl peroxybenzoate, 4,4-azobis(4-cyanovaleric acid), 1,1'-azobis(cyclohexanecarbonitrile), 2,2'-azobisisobutyronitrile, benzoyl peroxide, 2,2'-bis(tert-butylperoxy)butane, 1,1-bis(tert-butylperoxy)cyclohexane, 2,5-bis(tert-butylperoxy)-2,5-dimethylhexane, 2,5-bis(tert-butylperoxy)-2,5-dimethyl-3-hexane, and the like. peroxidase, bis(1-(tert-butylperoxy)-1-methylethyl)benzene, 1,1-bis(tert-butylperoxy)-3,3,5-trimethylcyclohexane, tert-butyl hydroperoxide, tert-butyl peracetate, tert-butyl peroxide, tert-butyl peroxybenzoate, tert-butylperoxyisopropyl carbonate, cumene, hydroperoxide, cyclohexanone peroxide, dicumyl peroxide, lauroyl peroxide, 2,4-pentanedione peroxide, peracetic acid, potassium persulfate, or any combination thereof.
[0044] In another aspect, crosslinking the membrane comprises exposing the membrane to heat in the presence of a thermal initiator and a crosslinking agent. In a further aspect, the crosslinking agent is selected from the group consisting of tetra(ethylene glycol) diacrylate, polyethylene glycol diacrylate, bis(2-(succinimidyl-oxycarbonyloxyl)ethyl)sulfone, di(n-succinimidyl)glutarate, disuccinimidyl tartrate, 3,3'-dithiobis(sulfosuccinimidyl)propionate, p-phenylenediisothiocyanate, sebacic acid bis(N-succinimidyl)ester, suberic acid bis(N-hydroxysuccinimide ester), APN-CHO, bromoacetic acid N-hydroxysuccinimide ester, CBTF, iodoacetic acid N-hydroxysuccinimide ester, maleimido-PEG-succinimidyl ester, maleimidoacetic acid N-Hydroxysuccinimide ester, Adipic dihydrazide, Alkyne-PEG-maleimide, APN-amine, APN-azide, APN-BCN, APN-COCl, Biotin-benzyl-tetrazine, Biotin-PEG-TPG, 1,11-Diazido-3,6,9-trioxaundecane, Dibenzocyclooctyne-N-hydroxysuccinimidyl ester, Dibenzocyclooctyne-maleimide, Dibenzocyclooctyne-PEG-maleimide, 4-(maleimido)phenylisocyanate (approximately 95% pure), 4,4'-methylenebis(phenylisocyanate), 3-(2-pyridyldithio) ) propionyl hydrazide, propargyl-N-hydroxylsuccinimidyl ester, PTAD-azide, sulfo-NHS-diazirine, sulfosuccinimidyl 4,4'-azipentanoate, 4-(N-maleimido)benzophenone, 4-azidophenacyl bromide, 5-azido-2-nitriobenzoic acid N-hydroxy succinimide ester, succinimidyl-[4-(psoralen-8-yloxy)]butyrate, 4-benzoylbenzoic acid N-succinimidyl ester, 1,4-bis[3-(2-pyridyldithio)propionamido]butane, bis-maleimidoethane, dithio-bis-maleimidoethane or any combination thereof.
[0045]
[0035] In yet another aspect, crosslinking the membrane comprises exposing the membrane to a transition metal. In a further aspect, the transition metal comprises ions of beryllium, magnesium, calcium, barium, manganese, copper, iron, or any combination thereof.
[0046]
[0036] In one aspect, the method further comprises incorporating a drug into the copolymer solution. In one aspect, the solvent is a miscible solvent. In one aspect, the drug is a hydrophilic drug. In a further aspect, the drug is in the form of finely divided microparticles. In one aspect, the method further comprises encapsulating cells within the membrane. In one aspect, the cells are engineered to produce insulin.
[0047] In one aspect, the method further comprises collecting the fibers in the form of a membrane, which comprises collecting the fibers with a rotating drum collector. In one aspect, the method further comprises collecting the fibers in the form of a membrane, which comprises collecting the fibers on a patterned structure. In a further aspect, the membrane comprises the shape of the patterned structure.
[0048] In one aspect, the solvent comprises DMF, acetone, acetonitrile, aniline, n-butyl acetate, cyclohexanone, chloroform, diacetone alcohol, di(ethylene glycol), dimethyle sulfoxide, dichloromethane, ethanol, ethyl acetate, ethylene dichloride, formic acid, glycerol, methanol, methyl acetate, morpholine, 2-nitropropane, 1-pentanol, n-propanol, pyridine, trifloroethanol, tetrahydrofuran, water, or any combination thereof. In one aspect, dissolving the base polymer and the functional polymer in the solvent comprises dissolving the base polymer and the functional polymer in the solvent in about a 1:1 ratio.
[0049]
[0039] In one aspect, dissolving the base polymer and the functional polymer in the solvent comprises dissolving the base polymer and the functional polymer in the solvent in a ratio of about 1:5. In another aspect, dissolving the base polymer and the functional polymer in the solvent comprises dissolving the base polymer and the functional polymer in the solvent in a ratio of about 1:10. In yet another aspect, dissolving the base polymer and the functional polymer in the solvent comprises dissolving the base polymer and the functional polymer in the solvent in a ratio of about 1:20. In one aspect, the base polymer and the functional polymer are present with the solvent at about 6% by weight to volume percent. In one aspect, the method further comprises an antioxidant, a macrophage inhibitor, or an anti-inflammatory agent.
[0050] In some aspects, the membrane is designed to allow the passage of cells. In further aspects, the membrane comprises a pore size of about 5 μm or more. In some aspects, the membrane is designed to block the passage of cells. In further aspects, the membrane comprises a pore size of about 3 μm or less. In some aspects, the membrane does not include a coating. In some aspects, the base is The base polymer includes PAN, PET, PLG, PHEMA, PCL or PLLA.
[0051] In a further aspect, the functional polymer comprises PEG, PEGMA, PEGDA or TEGDA. In one aspect, the base polymer is PAN. In one aspect, the functional polymer is PEGMA. In one aspect, the method further comprises an anti-fibrotic agent, an anti-inflammatory agent, a pro-angiogenic agent or a hydrophilizing agent. In one aspect, the functional polymer comprises a molecular weight in the range of about 500-4000 Da. In a further aspect, the functional polymer comprises a molecular weight in the range of about 1500-2500 Da.
[0052] In one aspect, D first is 10 -7 cm 2 / sec or more. first corresponds to the diffusion coefficient for insulin, and D second corresponds to the diffusion coefficient for IgG. In one aspect, the membrane comprises a tensile strength of about 1 MPa or greater. In a further aspect, the membrane comprises a tensile strength of about 1 MPa to about 100 MPa. In one aspect, the membrane comprises a Young's modulus of about 30 MPa or greater. In a further aspect, the membrane comprises a Young's modulus of about 10 MPa to about 100,000 MPa. In one aspect, the fibers comprise a diameter in the range of about 180 to 240 nm.
[0053] In other aspects, the fibers include a diameter in the range of about 520-560 nm. In one aspect, the fibers include a diameter of about 1000 nm or less. In one aspect, the membrane includes a thickness in the range of about 10-150 um. In a further aspect, the membrane includes a thickness in the range of about 80-120 um. In one aspect, the membrane is hydrophilic. In one aspect, the base polymer is designed to provide structural integrity to the membrane. In one aspect, the base polymer is hydrophobic.
[0054] In various aspects, the present disclosure provides a membrane for delivering cells or a therapeutic agent to a user, the membrane comprising a copolymer solution-based electrospun fiber, where the copolymer solution comprises a base polymer and a functional polymer designed to enable (1) crosslinking of the membrane and / or (2) conjugation of a therapeutic agent to the membrane, where the membrane comprises about 2 or more
[0055] [ka]
[0056] Ratio, where D first is the diffusion coefficient for a moiety containing a first molecular weight less than about 5 kDa, and D second is the diffusion coefficient for a moiety containing a second molecular weight greater than about 150 kDa.
[0057] In one aspect, the method further comprises crosslinking the membrane, wherein the crosslinking step comprises crosslinking the membrane to about 2 or more
[0058] [ka]
[0059] In one aspect, crosslinking the film comprises exposing the film to ultraviolet (UV) light in the presence of a photoinitiator. In a further aspect, the photoinitiator is acetophenone, anisoin, anthraquinone, benzil, benzoin, benzenetricarbonylchromium ... Benzoin ethyl ether, benzoin isobutyl ether, benzoin methyl ether, benzophenone, 3,3',4,4'-benzophenonetetracarboxylic dianhydride, 4-benzoylbiphenyl, 2-benzyl-2-(dimethylamino)-4'-morpholinobutyrophenone, 4,4'-bis(diethylamino)benzophenone, camphorquinone, 2-chlorothioxanthen-9-one, (cumene)cyclopentadienyliron(II) hexafluorophosphate, dibenzosuberenone, 2,2-diethoxyacetophenone, 4,4'-dihydroxybenzophenone, 2,2-dimethoxy-2-phenylacetophenone, 4-(dimethylamino)benzophenone, 4,4'-dimethylbenzyl, 2,5-dimethylbenzonphenone, 3,4-dimethylbenzophenone, diphenyl (2,4,6-trimethylbenzoyl)phosphine oxide, 4'-ethoxyacetophenone, 2-ethylanthraquinone, ferrocene, 3-hydroxyacetophenone, 4-hydroxyacetophenone, 1-hydroxycyclohexyl phenyl ketone, 2-hydroxy-2-methylpropiophenone, 2-methylbenzophenone, 3-methylbenzophenone, methylbenzoyl formate, 2-methyl-4'-(methylthio)-2-morpholinopropiophenone, phenanthrenequinone, 4'-phenoxyacetophenone, thioxanthen-9-one, triarylsulfonium, hexafluoroantimonate salts, triarylsulfonium hexafluorophosphate salts, or any combination thereof.
[0060] In one aspect, crosslinking the film comprises exposing the film to ultraviolet (UV) light in the presence of a photoinitiator and a crosslinking agent.In a further aspect, the crosslinker is tetra(ethylene glycol) diacrylate, polyethylene glycol diacrylate. diacralte), bis(2-(succinimidyl-oxycarbonyloxyl)ethyl)sulfone, di(n-succinimidyl)glutarate, disuccinimidyl tartrate, 3,3'-dithiobis(sulfosuccinimidyl)propionate, p-phenylenediisothiocyanate, sebacic acid bis(N-succinimidyl)ester, suberic acid bis(N-hydroxysuccinimide ester), APN-CHO, bromoacetic acid N-hydroxysuccinimide ester, CBTF, iodoacetic acid N-hydroxysuccinimide ester, maleimido-PEG-succinimidyl ester, maleimido-acetic acid N-hydroxysuccinimide ester, adipic acid dihydrazide, alkyne-PEG-maleimide, APN-amine, APN-azide, APN-BCN, APN-COCl, biotin-benzyl-tetrate radish, biotin-PEG-TPG, 1,11-diazido-3,6,9-trioxaundecane, dibenzocyclooctyne-N-hydroxysuccinimidyl ester, dibenzocyclooctyne-maleimide, dibenzocyclooctyne-PEG-maleimide, 4-(maleimido)phenylisocyanate (approximately 95% pure), 4,4'-methylenebis(phenylisocyanate), 3-(2-pyridyldithio)propionylhydrazide, propargyl-N-hydroxylsuccinimidyl ester, PTAD-azide, sulfo-NHS-diazirine, sulfosuccinimidyl 4,4'-azipentanoate, 4-(N-maleimido)benzophenone, 4-azidophenacyl bromide, 5-azido-2-nitrobenzoic acid N-hydroxysuccinimidyl ester acid N-hydroxy succinimide ester), succinimidyl-[4-(psoralen-8-yloxy)]butyrate, 4-benzoylbenzoic acid N-succinimidyl ester, 1,4-bis[3-(2-pyridyldithio)propionamido]butane, bis-maleimidoethane, dithio-bis-maleimidoethane, or any combination thereof.
[0061] In one aspect, crosslinking the membrane comprises exposing the membrane to heat in the presence of a thermal initiator. In a further aspect, the thermal initiator is selected from the group consisting of ammonium persulfate, tert-amyl peroxybenzoate, 4,4-azobis(4-cyanovaleric acid), 1,1'-azobis(cyanovaleric acid), and the like. cyclohexanecarbonitrile), 2,2'-azobisisobutyronitrile, benzoyl peroxide, 2,2'-bis(tert-butylperoxy)butane, 1,1-bis(tert-butylperoxy)cyclohexane, 2,5-bis(tert-butylperoxy)-2,5-dimethylhexane, 2,5-bis(tert-butylperoxy)-2,5-dimethyl-3-hexyne, bis(1-(tert-butylperoxy)-1-methylethyl)benzene , 1,1-bis(tert-butylperoxy)-3,3,5-trimethylcyclohexane, tert-butyl hydroperoxide, tert-butyl peracetate, tert-butyl peroxide, tert-butyl peroxybenzoate, tert-butylperoxyisopropyl carbonate, cumene, hydroperoxide, cyclohexanone peroxide, dicumyl peroxide, lauroyl peroxide, 2,4-pentanedione peroxide, peracetic acid, potassium persulfate, or any combination thereof.
[0062] In another aspect, crosslinking the membrane comprises exposing the membrane to heat in the presence of a thermal initiator and a crosslinking agent.In a further aspect, the crosslinker is tetra(ethylene glycol) diacrylate, polyethylene glycol diacrylate. diacralte), bis(2-(succinimidyl-oxycarbonyloxyl)ethyl)sulfone, di(n-succinimidyl)glutarate, disuccinimidyl tartrate, 3,3'-dithiobis(sulfosuccinimidyl)propionate, p-phenylenediisothiocyanate, sebacic acid bis(N-succinimidyl)ester, suberic acid bis(N-hydroxysuccinimide ester), APN-CHO, bromoacetic acid N-hydroxysuccinimide ester, CBTF, iodoacetic acid N-hydroxysuccinimide ester, maleimido-PEG-succinimidyl ester, maleimido-acetic acid N-hydroxysuccinimide ester, adipic acid dihydrazide, alkyne-PEG-maleimide, APN-amine, APN-azide, APN-BCN, APN-COCl, biotin-benzyl-tetrate radish, biotin-PEG-TPG, 1,11-diazido-3,6,9-trioxaundecane, dibenzocyclooctyne-N-hydroxysuccinimidyl ester, dibenzocyclooctyne-maleimide, dibenzocyclooctyne-PEG-maleimide, 4-(maleimido)phenylisocyanate (approximately 95% pure), 4,4'-methylenebis(phenylisocyanate), 3-(2-pyridyldithio)propionylhydrazide, propargyl-N-hydroxylsuccinimidyl ester, PTAD-azide, sulfo-NHS-diazirine, sulfosuccinimidyl 4,4'-azipentanoate, 4-(N-maleimido)benzophenone, 4-azidophenacyl bromide, 5-azido-2-nitrobenzoic acid N-hydroxysuccinimidyl ester acid N-hydroxy succinimide ester), succinimidyl-[4-(psoralen-8-yloxy)]butyrate, 4-benzoylbenzoic acid N-succinimidyl ester, 1,4-bis[3-(2-pyridyldithio)propionamido]butane, bis-maleimidoethane, dithio-bis-maleimidoethane, or any combination thereof.
[0063]
[0049] In yet another aspect, crosslinking the membrane comprises exposing the membrane to a transition metal. In a further aspect, the transition metal comprises ions of beryllium, magnesium, calcium, barium, manganese, copper, iron, or any combination thereof.
[0064]
[0050] In one aspect, the method further comprises incorporating a drug into the copolymer solution. In one aspect, the solvent is a miscible solvent. In one aspect, the drug is a hydrophilic drug. In a further aspect, the drug is in the form of finely divided microparticles. In one aspect, the method further comprises encapsulating cells within the membrane. In one aspect, the cells are engineered to produce insulin.
[0065] In one aspect, the method further comprises collecting the fibers in the form of a membrane, which comprises collecting the fibers using a rotating drum collector. In one aspect, the method further comprises collecting the fibers in the form of a membrane, which comprises collecting the fibers on a patterned structure. In a further aspect, the membrane comprises the shape of the patterned structure.
[0066] In one aspect, the solvent comprises DMF, acetone, acetonitrile, aniline, n-butyl acetate, cyclohexanone, chloroform, diacetone alcohol, di(ethylene glycol), dimethylsulfoxide, dichloromethane, ethanol, ethyl acetate, ethylene dichloride, formic acid, glycerol, methanol, methyl acetate, morpholine, 2-nitropropane, 1-pentanol, n-propanol, pyridine, trifloroethanol, tetrahydrofuran, water, or any combination thereof. In one aspect, dissolving the base polymer and the functional polymer in the solvent comprises dissolving the base polymer and the functional polymer in the solvent in about a 1:1 ratio.
[0067]
[0053] In one aspect, dissolving the base polymer and the functional polymer in the solvent comprises dissolving the base polymer and the functional polymer in the solvent in a ratio of about 1:5. In another aspect, dissolving the base polymer and the functional polymer in the solvent comprises dissolving the base polymer and the functional polymer in the solvent in a ratio of about 1:10. In yet another aspect, dissolving the base polymer and the functional polymer in the solvent comprises dissolving the base polymer and the functional polymer in the solvent in a ratio of about 1:20. In one aspect, the base polymer and the functional polymer are present with the solvent at about 6% by weight to volume percent. In one aspect, the method further comprises an antioxidant, a macrophage inhibitor, or an anti-inflammatory agent.
[0068] In some aspects, the membrane is designed to allow the passage of cells. In further aspects, the membrane comprises a pore size of about 5 μm or more. In some aspects, the membrane is designed to block the passage of cells. In further aspects, the membrane comprises a pore size of about 3 μm or less. In some aspects, the membrane does not include a coating. In some aspects, the base polymer comprises PAN, PET, PLG, PHEMA, PCL, or PLLA.
[0069] In a further aspect, the functional polymer comprises PEG, PEGMA, PEGDA or TEGDA. In one aspect, the base polymer is PAN. In one aspect, the functional polymer is PEGMA. In one aspect, the method further comprises an anti-fibrotic agent, an anti-inflammatory agent, a pro-angiogenic agent or a hydrophilizing agent. In one aspect, the functional polymer comprises a molecular weight in the range of about 500-4000 Da. In a further aspect, the functional polymer comprises a molecular weight in the range of about 1500-2500 Da.
[0070] In one aspect, D first is 10 -7 cm 2 / sec or more. firstcorresponds to the diffusion coefficient for insulin, and D second corresponds to the diffusion coefficient for IgG. In one aspect, the membrane comprises a tensile strength of about 1 MPa or greater. In a further aspect, the membrane comprises a tensile strength of about 1 MPa to about 100 MPa. In one aspect, the membrane comprises a Young's modulus of about 30 MPa or greater. In a further aspect, the membrane comprises a Young's modulus of about 10 MPa to about 100,000 MPa. In one aspect, the fibers comprise a diameter in the range of about 180 to 240 nm.
[0071] In another aspect, the fibers include a diameter in the range of about 520-560 nm. In one aspect, the fibers include a diameter of about 1000 nm or less. In one aspect, the membrane includes a thickness in the range of about 10-150 um. In a further aspect, the membrane includes a thickness of about 80-120 um. 0 um range. In some aspects, the membrane is hydrophilic. In some aspects, the base polymer is designed to provide structural integrity to the membrane. In some aspects, the base polymer is hydrophobic.
[0072] Incorporation by Reference
[0058] All publications, patents, and patent applications mentioned in this specification are incorporated by reference into this specification to the same extent as if each individual publication, patent, or patent application was specifically and individually indicated to be incorporated by reference.
[0073]
[0059] The patent or application file contains at least one drawing executed in color. Copies of this patent or patent application publication with color drawing(s) will be provided by the Office upon request and payment of the necessary fee. The novel features of the invention are set forth with particularity in the appended claims. A better understanding of the features and advantages of the present invention will be obtained by reference to the following detailed description setting forth illustrative embodiments in which the principles of the invention are utilized and the accompanying drawings, in which: [Brief description of the drawings]
[0074] [Figure 1A] FIG. 1A illustrates a scanning electron microscopy (SEM) image of an electrospun polymer according to an embodiment. [Figure 1B] FIG. 1B illustrates the release profile of molecules in electrospun polymeric membranes having different filament diameters according to an embodiment. [Figure 2A] FIG. 2A illustrates the diffusion of different molecules from an electrospun polymer membrane having 540 nm diameter filaments according to an embodiment. [Figure 2B] FIG. 2B illustrates the diffusion of different molecules from an electrospun polymer membrane having 202 nm diameter filaments according to an embodiment. [Figure 3A] FIG. 3A illustrates the diffusion coefficients of electrospun polymer membranes fabricated from poly(acrylonitrile) (PAN) compared to a Biopore ePTFE membrane according to an embodiment. [Figure 3B] FIG. 3B illustrates the flux of a 4 kDa solute across a range of electrospun polymer membranes in both the uncrosslinked and crosslinked states. [Figure 4A] FIG. 4A illustrates the epididymal fat pad of a mouse implanted with a cell-loaded planar device constructed from an electrospun polymer membrane according to an embodiment. [Figure 4B] FIG. 4B illustrates host cell ingress into the wall of an electrospun polymer membrane after implantation into the epididymal fat pad of a mouse according to an embodiment. [Diagram 5] FIG. 5 illustrates the test system used to measure the burst strength of planar devices fabricated from electrospun polymer films. [Figure 6A] FIG. 6A illustrates the pressure (psi) at which an electrospun polymeric membrane bursts according to an embodiment. [Figure 6B] FIG. 6B illustrates the maximum load (mN) that can be withstood by an electrospun polymer membrane according to ASTM D790-03, according to an embodiment. [Figure 7A] FIG. 7A illustrates an SEM image of an uncrosslinked electrospun polymer membrane according to an embodiment. [Figure 7B] FIG. 7B illustrates an SEM image of a crosslinked electrospun polymer membrane according to an embodiment. [Figure 7C] FIG. 7C shows the release profile of molecules from electrospun polymeric membranes of the present disclosure with different degrees of crosslinking according to an embodiment. [Figure 8A] FIG. 8A illustrates how a photoinitiator and ultraviolet (UV) light affect the structure of PEGMA, a secondary crosslinker, and TEGDA with PEGMA and TEGDA according to an embodiment. [Figure 8B]
[0075] FIG. 8B illustrates Fourier transform infrared spectroscopy (FTIR) results showing the transition of C═C bonds to C—C bonds in the PEGMA polymer upon crosslinking according to an embodiment. [Figure 9A]
[0076] FIG. 9A illustrates the tensile strength (MPa) of a crosslinked functional electrospun polymer membrane according to an embodiment. [Figure 9B]
[0077] FIG. 9B illustrates Young's modulus (MPa) of a crosslinked functional electrospun polymer membrane according to an embodiment. [Figure 9C]
[0078] FIG. 9C illustrates the release profile of molecules over time for various polymeric membranes of the present disclosure according to embodiments. [Figure 10]
[0079] FIG. 10 illustrates an SEM image showing the ultrastructure of a functional electrospun polymer membrane after UV crosslinking according to an embodiment. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0075]
[0080] The present disclosure provides devices, compositions and methods for delivering therapeutic agents. For example, various components and features of the device, as well as methods for making and using such devices, are disclosed herein. In some cases, the functional electrospun polymer can be crosslinked and / or can be provided in the form of a membrane. Although the term membrane is primarily used herein, it should be understood that membrane can refer to any shape or form of the functional polymer described herein and can be utilized for any purpose. For example, the membrane can be thin or not thin, can act as a boundary or lining or partition, and can allow or not selective passage of components or different parts. In some cases, the membrane can be provided as a device or can be integrated with a device, such as a medical device.
[0076]
[0081] Open terms such as "contain," "containing," "include," "including," etc. mean comprising.
[0077]
[0082] The singular forms "a," "an," and "the" are used herein to include plural references unless the context clearly dictates otherwise.
[0083] Unless otherwise indicated, some aspects herein contemplate numerical ranges. When numerical ranges are provided, the ranges can include the endpoints of the ranges unless otherwise indicated. Unless otherwise indicated, numerical ranges can include all values and subranges therein as if expressly written.
[0078]
[0084] The term "about" in reference to a reference numerical value can include values in a range of plus or minus 10% from that value. For example, the amount "about 10" includes amounts from 9 to 11, including the reference numbers 9, 10, and 11. The term "about" in reference to a reference numerical value can also include values in a range of plus or minus 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, or 1% from that value.
[0079]
[0085] As used herein, the term "membrane" may refer to a membrane made by any technique. A subset of "membrane" may include "polymeric membranes" where the membrane is composed of a polymer. A subset of "membrane" may also include "electrospun polymeric membranes" as described in this disclosure, where the polymeric membrane is made using the electrospinning process disclosed herein. A subset of "electrospun polymeric membranes" may include "crosslinked functionalized electrospun polymeric membranes" where the electrospun polymeric membrane is crosslinked via a functionalized polymer. All properties and characteristics described herein, such as diffusion ratios of encapsulated moieties, mechanical properties, etc., may be applicable to membranes, polymeric membranes, electrospun polymeric membranes, crosslinked or functionalized electrospun polymeric membranes.
[0080]
[0086] The membranes (e.g., electrospun polymer membranes) described herein may offer advantages in terms of their ease of manufacture and scale-up, and the ability to adjust various properties of the membrane (e.g., electrospun polymer membrane) based on the desired outcome. For example, the composition and method of making the membrane (e.g., electrospun polymer membrane) can be varied to adjust the diffusion coefficient of encapsulant or penetrant, mechanical properties (e.g., tensile strength and Young's modulus) and / or long-term structural integrity. These aspects of the membrane (e.g., electrospun polymer membrane) can be adjusted as desired by controlling the individual fiber diameter, the thickness of the membrane (e.g., electrospun polymer membrane), the selection of polymer and crosslinker components, the amount of polymer (e.g., base polymer and functional polymer), the amount of crosslinked polymer or crosslinker, the method of crosslinking, or any combination thereof.
[0081]
[0087] The functional electrospun polymers of the present disclosure can be used in many applications, from providing filtration devices that can be used in research and development to actual implantable therapeutic products that provide relief to subjects with chronic illnesses. As an example, the functional electrospun polymers can be utilized for filtration purposes. For example, the membranes of the present disclosure (e.g., electrospun polymer membranes) can be used as cell filtration devices or as filtration devices to eliminate high molecular weight moieties (e.g., large proteins). As another example, the functional electrospun polymers can be utilized for the purpose of providing therapeutic benefits, for example, with a membrane containing a therapeutic or effective agent that can release the effective agent at a desired rate. In some cases, the polymer-based membrane or device can be delivered to a subject in need thereof. For example, the polymer-based membrane can be placed adjacent to the subject or implanted within the subject. As used herein, a membrane can refer to an assembly of functional polymers.
[0082]
[0088] In some cases, the polymer-based membrane can include a therapeutic component (also referred to herein as a therapeutic moiety). In some cases, the therapeutic component can be designed to be released from the membrane. For example, the membrane can include cells (e.g., engineered cells) designed to release a therapeutic moiety and / or drug that is released from the membrane. The polymer-based membrane can include features such as allowing diffusion or movement of the relevant moiety (e.g., therapeutic moiety) into or out of the membrane to provide an effective treatment to the patient or user. For example, the polymer-based membrane can include or be designed with a diffusion coefficient and / or pore structure that allows the relevant therapeutic moiety to diffuse out of the membrane at a desired rate. Alternatively, or in addition, the membrane can include features such as preventing, restricting, or minimizing diffusion or movement of the relevant moiety (e.g., host proteins, cells, etc.) into or out of the membrane. For example, the membrane can include or be designed with a diffusion coefficient and / or pore size that can impede the movement of undesirable moieties into the membrane.
[0083]
[0089] In some cases, the polymer-based membrane or device can include features that strike a balance between providing easy diffusion of relevant moieties (e.g., therapeutic moieties) from the device into the subject while limiting infiltration of undesirable moieties (e.g., host proteins, e.g., IgG and BSA). In some cases, the polymer-based device that encapsulates cells that secrete therapeutic moieties can be designed or fabricated to prevent the cells from migrating into and / or out of the polymer network while allowing release of the therapeutic moiety. Alternatively, or in addition, the polymer-based membrane or device can be designed or fabricated to allow the cells to migrate into and / or out of the polymer network.
[0084]
[0090] The membranes described herein define the diffusion coefficient of the low molecular weight portion into the high molecular weight portion. D first / Dsecond The low molecular weight portion can be a therapeutic moiety, while the high molecular weight portion is a host infiltrate or cell. In some cases, crosslinking of the membranes described herein can provide the membrane with a desired property, such as the D-type cleavage properties mentioned above. first / D second In some cases, the ratio D first / D second The ratio can be 2 or more. Thus, the crosslinked functional membranes (e.g., electrospun polymer membranes) of the present disclosure can allow high flux of lower molecular weight therapeutic moieties while restricting the passage of higher molecular weight infiltrates or preventing engineered cells secreting low molecular weight therapeutic moieties from exiting the device. In some cases, the crosslinked nature of the functional membranes (e.g., electrospun polymer membranes) can further enhance the mechanical properties and structural integrity of the membranes disclosed herein.
[0085]
[0091] The membranes (e.g., electrospun polymer membranes) described herein can be engineered to include a base polymer and a functional polymer, each of which can be adjusted depending on the desired functionality or properties of the resulting membrane. As described above, the membranes can be further crosslinked to adjust the desired functionality or properties of the resulting membrane. Optionally, the membranes can include a crosslinking agent and a crosslinking initiator, as described in more detail below. The compositions and methods described herein allow for the development of novel crosslinked functional membranes (e.g., electrospun polymer membranes), which can be used for a variety of applications, including, but not limited to, implantable devices that can be implanted into a subject in need thereof for the purpose of treating a disease. In one example, the disease can be a chronic disease, such as diabetes. Methods of administration and methods of making crosslinked functional membranes (e.g., electrospun polymer membranes) are also disclosed herein.
[0086] Base Polymer
[0092] The membranes described herein can include or be made of a base polymer. The base polymer can include many different categories of polymers, including but not limited to polyacrylonitriles, polyacrylates, acrylic polymers, methacrylic polymers, polyethers, polyesters, polyurethanes, lactic acid polymers, glycolic acid polymers, cellulose, celluloid, fluoropolymers, nucleic acids, organosilicon polymers, peptides, polyamides, polyacrylamides, polycarbonates, polyaryletherketones, polyolefins, polysaccharides, proteins, tannins, and / or vinyl polymers. The base polymer can be biodegradable or non-biodegradable. In some cases, the base polymer can be biocompatible. The present disclosure provides a base polymer that is biocompatible and suitable for implantation into a subject. In some cases, the base polymer can be a copolymer, such as poly(lactic-co-glycolic acid) (PLGA), poly(fumaric-sebacic anhydride (pFASA), poly(acrylonitrile-co-butadiene), poly(acrylonitrile-co-butyl methacrylate), poly(acrylonitrile-co-vinylidene chloride), or poly(acrylamide) copolymer. In other examples, the base polymer can be a diblock or triblock polymer. For example, a diblock or triblock polymer could be a fusion of a base polymer and another base polymer. In another example, a diblock or triblock polymer could be a fusion of a base polymer and a functional polymer (e.g., PLGA-PEG).
[0087]
[0093] Controlled degradation can be achieved by incorporating a biodegradable polymer (e.g., PLA, PGA, PLGA, PDS, chitosan, etc.) into the base polymer solution. Varying the biodegradable / base polymer ratio, the molecular weight of the biodegradable polymer, and / or the electrospinning parameters allows for control of degradation kinetics to accommodate various physiological environments (e.g., In one exemplary embodiment, a biodegradable polymer (e.g., PLA, PGA, PLGA, PDS, chitosan) is electrospun independently or in the presence of a crosslinker (e.g., TEGDA) with a non-biodegradable polymer (e.g., PAN) to construct a biodegradable controlled release of a drug (e.g., CXCL12).
[0088]
[0094] The base polymer can be designed to provide structural integrity to the membrane described herein. In some cases, the base polymer can be hydrophobic. For example, a hydrophobic base polymer could be selected to stimulate a stronger foreign body response if desired. In some cases, a specific base polymer can be selected to design a polymer membrane according to a desired application. In some cases, a base polymer that is biocompatible, hydrophobic, and provides suitable structural integrity can be selected to design an implantable membrane. In further cases, a non-biodegradable polymer is selected to provide long-term structural integrity in biological conditions to design an implantable membrane. In some cases, the base polymer can be selected according to the desired elasticity, hydrophilicity, reactivity in conjugation chemistry, surface energy, optical properties, swelling, or ability to be electrospun with a desired filament diameter.
[0089]
[0095] The base polymer of the present disclosure may be any of the following: polyacrylonitrile (PAN), polyethylene terephthalate (PET), poly(d,L-lactide-co-glycolide) (PLG), poly(2-hydroxyethyl methacrylate) (PHEMA), polyacrylonitrile (PCL), poly(acrylonitrile)-poly(vinyl chloride) (PAN-PVC) copolymers, polycarbonate (PC), polydimethylsiloxane (PDMS), polyethylene (PE), polyethylene glycol (PEG, also known as poly(ethylene oxide) or PEO), polyethersulfone (PES), poly(glycolic acid) (PGA), poly(methyl methacrylate) (PMM ... A), polysulfone (PSf), polystyrene (PSt), polytetrafluoroethylene (PTFE), polyurethane (PU), poly(vinyl acetate) (PVAc), poly(vinyl alcohol) (PVA), polyvinylidene fluoride (PVDF), polylactic acid (PLA) (including poly(D,L-lactic acid), poly(L-lactic acid)), cellulose, celluloid, fluoropolymers, nucleic acids, organosilicon polymers, peptides, polyamides, polyacrylamides, polycarbonates, polyaryletherketones, polyolefins, polysaccharides, proteins, tannins, vinyl polymers, or any combination thereof.
[0090]
[0096] In a typical embodiment, the membrane (e.g., electrospun polymer membrane) comprises a base polymer of PAN. In other embodiments, the membrane (e.g., electrospun polymer membrane) can have a base polymer of PAN, PCL, EVA, PLLA, pFASA, or any combination thereof. Any combination of the polymers described herein can be used to form the base polymer composition herein. For example, any one base polymer above, any two base polymers above, any three base polymers above, any four base polymers above, any five base polymers above, or more can be used in combination to form the base polymer component of the membrane (e.g., electrospun polymer membrane). Excipients that can be included in any of the membranes described herein (e.g., electrospun polymer membranes) include excipients that can enhance or control tissue integration, including extracellular matrix proteins (laminin, collagen, etc.), hydrogels (alginate, chitosan, agarose, carboxymethylcellulose), gelatin, poly(dimethylsiloxane), poly(hydroxyethyl methacrylate), poly(ethylene glycol) and microtextured versions thereof.
[0091]
[0097] The base polymer of the present disclosure can have a range of molecular weights, including from about 10 kDa to about 2,000 kDa. For example, a base polymer of the present disclosure, such as PAN, can have a molecular weight of 150,000 Da.
[0092] Functional Polymers
[0098] The membranes of the present disclosure may, in some cases, include or be made from functional polymers. The functional polymers may be subject to further synthetic manipulations to impart additional properties to the membrane. For example, the functional polymers may be designed to allow cross-linking of the membrane. Alternatively, or in addition, the functional polymers may be designed to allow conjugation of therapeutic agents to the membrane. In some cases, the functional polymers may impart properties to the membrane, such as improved mechanical strength and / or device integrity. The functional polymers described herein may include, but are not limited to, polyethylene glycol (PEG), poly(ethylene glycol) methacylate (PEGMA), poly(ethylene glycol) diacylate (PEGDA), tetraethylene glycol diacrylate (TEGDA), or any combination thereof.
[0093]
[0099] Functional polymers can also include maleimide-PEG-succinimidyl ester, alkyne-PEG-maleimide, biotin-PEG-TPG, dibenzocyclooctyne-PEG-maleimide. Non-polymeric agents include bis(2-(succinimidyl-oxycarbonyloxyl)ethyl)sulfone, di(n-succinimidyl)glutarate, disuccinimidyl tartrate, 3,3'-dithiobis(sulfosuccinimidyl)propionate, p-phenylenediisothiocyanate, sebacic acid bis(N-succinimidyl)ester, suberic acid bis(N-hydroxysuccinimide ester), APN-CHO, bromoacetic acid N-hydroxysuccinimide ester, CBTF, iodoacetic acid N-hydroxysuccinimide ester, maleimidoacetic acid N-hydroxysuccinimide ester, adipic acid dihydrazide, APN-amine, APN-azide, APN-BCN, APN-COCl, biotin-benzyl-tetrazine. , 1,11-Diazido-3,6,9-trioxaundecane, Dibenzocyclooctyne-N-hydroxysuccinimidyl ester, Dibenzocyclooctyne-maleimide, 4-(maleimido)phenylisocyanate (approximately 95% pure), 4,4'-methylenebis(phenylisocyanate), 3-(2-pyridyldithio)propionylhydrazide, Propargyl-N-hydroxylsuccinimidyl ester, PTAD-azide, Sulfo-NHS-diazirine, Sulfosuccinimidyl 4,4'-azipentanoate, 4-(N-maleimido)benzophenone, 4-Azidophenacyl bromide, 5-Azido-2-nitrobenzoic acid N-hydroxysuccinimidyl ester acid N-hydroxy succinimide ester), succinimidyl-[4-(psoralen-8-yloxy)]butyrate, 4-benzoylbenzoic acid N-succinimidyl ester, 1,4-bis[3-(2-pyridyldithio)propionamido]butane, bis-maleimidoethane, dithio-bis-maleimidoethane, etc. In an exemplary embodiment, the membrane (e.g., electrospun polymer membrane) comprises PEGMA as the functional polymer.Alternatively, PEGMA and TEGDA can be used as the functional polymer in the membranes (eg, electrospun polymer membranes) of the present disclosure.
[0094]
[0100] A functional polymer may also be referred to herein as a "crosslinker." In some embodiments, further synthetic operations that a functional polymer is amenable to include crosslinking. For example, after incorporation in a film of the present disclosure (e.g., an electrospun polymer film), the functional polymer may be crosslinked by exposure to ultraviolet (UV) light, heat, transition metals, chemical reaction-based crosslinking, or any of the above. The membranes may be crosslinked by any combination. For example, the exemplary membranes (e.g., electrospun polymer membranes) of the present disclosure may include PAN as the base polymer and PEGMA or PEGMA and TEGDA as the functional polymers. These membranes (e.g., electrospun polymer membranes) may be further exposed to UV light in the presence of a photoinitiator to promote crosslinking of the membrane, thus improving the mechanical properties and device integrity, and also modulating the release of any loaded agents (e.g., cells or drugs).
[0095]
[0101] In some cases, the functional polymer can provide the ability to conjugate a therapeutic moiety to the membrane. This can be accomplished by the presence of activated sites, which can form chemical bonds or physical interactions with the conjugated drug or therapeutic agent on the activated sites. In some cases, the therapeutic moiety can be included in or part of the fibers of the membrane. For example, the drug can be dispersed in the polymer solution prior to electrospinning of the polymer membrane, as described herein. Alternatively, or in addition, the drug can be conjugated to the membrane after the polymer solution is electrospun to form the membrane. The drug can be incorporated into the spun fiber or can be attached post-facto using coupling chemistry. As used herein, the therapeutic moiety can refer to a drug, and the terms can be used interchangeably. However, it should be understood that the term "drug" is not meant to be limiting and can refer to any therapeutic moiety, including, but not limited to, prodrugs, small molecules, biological agents, peptides, proteins, and the like. The drug can be hydrophilic or hydrophobic. In some cases, the drug can be in the form of finely divided microparticles. In some cases, the medications could include anti-inflammatory agents such as cilostazol, dexamethasone and triamcinolone, anti-colony stimulating factors and other immunomodulatory cytokines and factors.
[0096]
[0102] Functional polymers can also be defined by the presence of reactive functional groups for crosslinking and / or conjugation of drugs.Reactive functional groups can include, but are not limited to, carboxylate, hydroxyl, amide, azide, maleimide, isocyanate, aziridine, acrylalkene, triaziridine, epoxy, activated alkene, aldehyde, ketone, acrylate, alcohol, acrylamide, multicarboxylic acid, metal alkoxide, acetylene, alkene, conjugated diene, alkyne or cyanide groups.Specific crosslinking strategies are further described below.
[0097]
[0103] Any mixture of the above functional polymers can be used to form the functional polymer composition herein. For example, any one of the above functional polymers, any two of the above functional polymers, any three of the above functional polymers, any four of the above functional polymers, or any five of the above functional polymers can be used in combination to form the functional polymer component of a membrane (e.g., an electrospun polymer membrane).
[0098] Base Polymer and Functional Polymer
[0104] In some cases, the membranes described herein can include both base polymers and functional polymers. For example, the base polymer and functional polymer can each be dissolved in a desired solvent as described herein and mixed together before electrospinning. The membranes can include or be made with different mass ratios of base polymer to functional polymer. For example, the membranes (e.g., electrospun polymer membranes) can be made with a base polymer to functional polymer ratio of about 5000 to 1, 2000 to 1, 1000 to 1, 800 to 1, 600 to 1, 400 to 1, 200 to 1, 100 to 1, 50 to 1, 20 to 1, 10 to 1, 5 to 1, 2 to 1, 1 to 1, 1 to 2, 1 to 5, 1 to 10, 1 to 20, 1 to 50, 1 to 10 ... It may include mass ratios (w / w) of 0, 1 to 400, 1 to 600, 1 to 800, 1 to 1000, 1 to 2000, 1 to 5000, or any value therebetween or greater. In some cases, the membrane (e.g., electrospun polymer membrane) can include a mass ratio (w / w) of functional polymer to base polymer in the range of about 0.001 to 1000, 0.001 to 100, 0.001 to 10, 0.001 to 1, 0.001 to 0.1, 0.001 to 0.01, 0.001 to 0.1, 0.01 to 1000, 0.01 to 100, 0.01 to 10, 0.01 to 1, 0.01 to 0.1, 0.1 to 1000, 0.1 to 100, 0.1 to 10, 0.1 to 1, 1 to 1000, 1 to 100, 1 to 10, 10 to 1000, 10 to 100, or 100 to 1000.
[0099]
[0105] In some cases, the base polymer can be PAN and the functional polymer can be PEGMA. The membrane (e.g., electrospun polymer membrane) can include the same ratio of functional polymer compared to the base polymer, at least 5 times higher base polymer than the functional polymer, at least 6 times higher base polymer than the functional polymer, at least 7 times higher base polymer than the functional polymer, at least 8 times higher base polymer than the functional polymer, at least 9 times higher base polymer than the functional polymer, at least 10 times higher base polymer than the functional polymer, at least 11 times higher base polymer than the functional polymer, at least 12 times higher base polymer than the functional polymer, at least 13 times higher base polymer than the functional polymer, at least 14 times higher base polymer than the functional polymer, at least 15 times higher base polymer than the functional polymer, at least 16 times higher base polymer than the functional polymer, at least 17 times higher base polymer than the functional polymer, at least 18 times higher base polymer than the functional polymer, at least 19 times higher base polymer than the functional polymer, or at least 20 times higher base polymer than the functional polymer. Thus, a functional polymer such as PEGMA can be incorporated into a membrane (e.g., an electrospun polymer membrane) at at least 0.5% (w / w) to at least 50% (w / w) of the total polymer composition. In other cases, the functional polymer can be incorporated at a lower percentage, such as at least 2%, at least 3%, at least 4%, at least 5%, at least 6%, or at least 7% of the total polymer composition.
[0100]
[0106] In some cases, the incorporation of a higher percentage of crosslinker or functional polymer may result in attenuated release of the encapsulated moiety. For example, a higher percentage of crosslinker may result in more crosslinking, which may result in a decrease in the porosity (e.g., pore size) of the membrane, resulting in attenuated release of the encapsulated moiety. For example, as shown in FIG. 9C, changing the ratio of PEGMA to PAN in the membrane (e.g., electrospun polymer membrane) from 1:5 PEGMA:PAN to 1:10 PEGMA:PAN resulted in an increased burst release of the drug. For example, as shown in FIG. 9C, increasing the concentration of PEGMA in the membrane from 1:10 PEGMA:PAN to 1:5 PEGMA PAN may result in a decrease in the flux of the drug from the membrane. Also, as shown in FIG. 7C, changing the ratio of PEGMA to PAN from 1:10 to 1:5 resulted in more crosslinking and attenuated release of the drug from the membrane (e.g., electrospun polymer membrane).
[0101]
[0107] The ratio of base polymer to functional polymer can affect the burst pressure of the membrane (e.g., electrospun polymer membrane). As shown in FIG. 6A, increasing the amount of base polymer (PAN) in the membrane (e.g., electrospun polymer membrane) can increase the burst pressure. Thus, one strategy to improve the pressure that the membrane (e.g., electrospun polymer membrane) of the present disclosure can withstand before bursting can be to increase the amount of base polymer (e.g., PAN) and / or reduce the amount of functional polymer (e.g., PEG) used in the composition. The ratio of base polymer to functional polymer can affect the burst pressure of the membrane (e.g., electrospun polymer membrane). The amount of base polymer (PAN) in the membrane (e.g., electrospun polymer membrane) can also affect the maximum load. As shown in Figure 6B, increasing the amount of base polymer (PAN) in the membrane (e.g., electrospun polymer membrane) can increase the maximum load. Therefore, one strategy to improve the maximum load that the membrane (e.g., electrospun polymer membrane) of the present disclosure can withstand before failure is to increase the amount of base polymer (e.g., PAN) and / or decrease the amount of functional polymer (e.g., PEG).
[0102]
[0108] Functional polymers conforming to the present disclosure can have molecular weights ranging from 100 Da to 10,000 Da. In some cases, the base polymers of the present disclosure can have molecular weights ranging from 100 Da, 200 Da, 400 Da, 600 Da, 800 Da, 1,000 Da, 1,200 Da, 1,500 Da, 2,000 Da, 2,500 Da, 3,000 Da, 3,500 Da, 4,000 Da, 4,500 Da, 5,000 Da, 6,000 Da, 7,000 Da, 8,000 Da, 9,000 Da, 10,000 Da, 11,000 Da, 12,000 Da, 13,000 Da, 14,000 Da, 15,000 Da, 16,000 Da, 17,000 Da, 18,000 Da, 19,000 Da, 21,000 Da, 22,000 Da, 23,000 Da, 24,000 Da, 25,000 Da, 26,000 Da, 27,000 Da, 28,000 Da, 29,000 Da, 30,000 Da, 31,000 Da, 32,000 Da, 33,000 Da, 34,000 Da, 35,000 Da, 36,000 Da, 37,000 Da, 38,000 Da, 39 ... ,000Da, 8,000Da, 9,000Da, 10,000Da, 12,000Da, 14,000Da, 16,000Da, 18,000Da, 20 ,000Da, 30,000Da, 40,000Da, 50,000Da, 60,000Da, 70,000Da, 80,000Da, 90,000Da, 100,000Da, 150,000Da, 200,000Da, 250,000Da, 300,000Da, 350,000Da, 400,000Da, 450,000Da, 500,000Da, 600,000Da, 700,000Da, 800,000Da, 900,000Da, 1,000,000D The molecular weight of the compound may be less than or equal to 1,100,000 Da, 1,200,000 Da, 1,300,000 Da, 1,400,000 Da, 1,500,000 Da, 1,600,000 Da, 1,700,000 Da, 1,800,000 Da, 1,900,000 Da or 2,000,000 Da.In some cases, the base polymer of the present disclosure may be 100 Da, 200 Da, 400 Da, 600 Da, 800 Da, 1000 Da, 1200 Da, 1500 Da, 2000 Da, 2500 Da, 3000 Da, 3500 Da, 4000 Da, 4500 Da, 5000 Da, 6000 Da, 7000 Da, 80 00Da, 9000Da, 10000Da, 12000Da, 14000Da, 16000Da, 18000Da, 20000Da, 30,000Da , 40,000Da, 50,000Da, 60,000Da, 70,000Da, 80,000Da, 90,000Da, 100,000Da, 150 ,000Da, 200,000Da, 250,000Da, 300,000Da, 350,000Da, 400,000Da, 450,000Da, 5 00,000Da, 600,000Da, 700,000Da, 800,000Da, 900,000Da, 1,000,000Da, 1,100,0 In some embodiments, the molecular weight of the compound may be greater than or equal to 1,000 Da, 1,200,000 Da, 1,300,000 Da, 1,400,000 Da, 1,500,000 Da, 1,600,000 Da, 1,700,000 Da, 1,800,000 Da, 1,900,000 Da or even up to 2,000,000 Da.In some cases, the base polymer of the present disclosure may be from about 100 Da to about 200 Da, from about 200 Da to about 400 Da, from about 400 Da to about 600 Da, from about 600 Da to about 800 Da, from about 800 Da to about 1,000 Da, from about 1,000 Da to about 1,200 Da, from about 1,200 Da to about 1,500 Da, from about 1,500 Da to about 2,000 Da, or from about 2,000 Da. Da to about 2,500 Da, about 2,500 Da to about 3,000 Da, about 3,000 Da to about 3,500 Da, about 3,500 Da to about 4,000 Da, about 4,000 Da to about 4,500 Da, about 4,500 Da to about 5,000 Da, about 5,000 Da to about 6,000 Da, about 6,000 Da to about 7,000 Da, about 7,000 Da to about 8,0 00 Da, about 8,000 Da to about 9,000 Da, about 9,000 Da to about 10,000 Da, about 10,000 Da to about 12,000 Da, about 12,000 Da to about 14,000 Da, about 14,000 Da to about 16,000 Da, about 16,000 Da to about 18,000 Da, about 18,000 Da to about 20,000 Da, about 20,000 Da ~ about 30,000 Da, about 30,000 Da to about 40,000 Da, about 40,000 Da to about 50,000 Da, about 50,000 Da to about 60,000 Da, about 60,000 Da to about 70,000 Da, about 70,000 Da to about 80,000 Da, about 80,000 Da to about 90,000 Da, about 90,000 Da to about 100,000 Da. a, about 100,000 Da to about 150,000 Da, about 150,000 Da to about 200,000 Da, about 200,000 Da to about 250,000 Da, about 250,000 Da to about 300,000 Da, about 300,000 Da to about 350,000 Da, about 350,000 Da to about 400,000 Da, about 400,000 Da to about 450,000 Da, about 450,000 Da to about 500,000 Da, about 500,000 Da to about 600,000 Da, about 600,000 Da to about 700,000 Da, about 700,000 Da to about 800,000 Da, about 800,000 Da to about 900,000 Da, about 900,000 Da to about 1,000,0 00 Da, about 1,000,000 Da to about 1,100,000 Da, about 1,100,000 Da to about 1,200,000 Da, about 1,200,000 Da to about 1,300,000 Da, about 1,300,000 Da to about 1,400,000 Da, about 1,400,000 Da to about 1,500,000 Da, about 1,500, The functional polymer may have a molecular weight within the range of about 1,000 Da to about 1,600,000 Da, about 1,600,000 Da to about 1,700,000 Da, about 1,700,000 Da to about 1,800,000 Da, about 1,800,000 Da to about 1,900,000 Da, or about 1,900,000 Da to about 2,000,000 Da. Functional polymers compatible with the present disclosure may have a molecular weight of 1500 Da to 2500 Da. In some cases, the functional polymers of the present disclosure can have a molecular weight of less than or equal to 100 Da, 200 Da, 400 Da, 600 Da, 800 Da, 1000 Da, 1200 Da, 1500 Da, 2000 Da, 2500 Da, 3000 Da, 3500 Da, 4000 Da, 4500 Da, 5000 Da, 6000 Da, 7000 Da, 8000 Da, 9000 Da, 10000 Da, 12000 Da, 14000 Da, 16000 Da, 18000 Da, or 20000 Da.In some cases, the functional polymers of the present disclosure can have a molecular weight of 100 Da, 200 Da, 400 Da, 600 Da, 800 Da, 1000 Da, 1200 Da, 1500 Da, 2000 Da, 2500 Da, 3000 Da, 3500 Da, 4000 Da, 4500 Da, 5000 Da, 6000 Da, 7000 Da, 8000 Da, 9000 Da, 10000 Da, 12000 Da, 14000 Da, 16000 Da, 18000 Da, or 20000 Da or more. In some cases, the functional polymer of the present disclosure can have a molecular weight within the range of 100 Da, 200 Da, 400 Da, 600 Da, 800 Da, 1000 Da, 1200 Da, 1500 Da, 2000 Da, 2500 Da, 3000 Da, 3500 Da, 4000 Da, 4500 Da, 5000 Da, 6000 Da, 7000 Da, 8000 Da, 9000 Da, 10000 Da, 12000 Da, 14000 Da, 16000 Da, 18000 Da, or 20000 Da. In some cases, the functional polymer (e.g., PEGMA) incorporated into the membrane (e.g., electrospun polymer membrane) can have a molecular weight of 480 Da. In other cases, the functional polymer (eg, PEGMA) incorporated into the membrane (eg, electrospun polymer membrane) can have a molecular weight of 2000 Da.
[0103]
[0109] The molecular weight of the functional polymer may be an important factor in determining the structure and / or functionality of the polymer membrane of the present disclosure. Figure 10 demonstrates the change in coating of crosslinked functional membranes (e.g., electrospun polymer membranes) with different molecular weights of PEGMA (including 480 Da and 2 kDa) made from PAN / PEGMA polymer and TEGDA in a ratio of 1 / 5. Lower molecular weight functional polymers may have more reactive functional groups that are crosslinking points at a given chain length. In comparison, higher molecular weight functional polymers may have fewer reactive functional groups that are crosslinking points at the same given chain length. As a result, when crosslinked, the lower molecular weight PEGMA in the crosslinked functional membrane (e.g., electrospun polymer membrane) may result in an overcoating that is significantly less porous than that in the higher molecular weight PEGMA incorporated in the membrane, as shown in Figure 10.
[0104]
[0110] Furthermore, as shown in FIG. 9A, without TEGDA, decreasing the molecular weight of PEGMA from 2 kDa to 480 Da resulted in a decrease in tensile strength. As shown in Figure 9B, without TEGDA, decreasing the molecular weight of PEGMA from 2 kDa to 480 Da results in a decrease in Young's modulus. However, in crosslinked functional membranes (e.g., electrospun polymer membranes) with TEGDA, decreasing the PEGMA molecular weight increased the Young's modulus. Thus, the molecular weight of the functional polymer can affect both the tensile strength and Young's modulus.
[0105]
[0111] As described herein, the base polymer and / or the functional polymer can each be dissolved in a desired solvent and mixed together prior to electrospinning. The polymer, such as the base polymer or the functional polymer described herein, can be dissolved in dimethylformamide (DMF), acetone, acetonitrile, aniline, n-butyl acetate, cyclohexanone, chloroform, diacetone alcohol, di(ethylene glycol), dimethylsulfoxide, dichloromethane, ethanol, ethyl acetate, ethylene dichloride, formic acid, glycerol, methanol, methyl acetate, morpholine, 2-nitropropane, 1-pentanol, n-propanol, pyridine, trifloroethanol, tetrahydrofuran, water, or any combination of these solvents.
[0106] Electrospinning
[0112] A polymer solution containing any one or any combination of the polymers described herein can be electrospun using an electrospinning apparatus that includes an emitter and a collector. Any form of fiber collected can be called a membrane. The polymer solution is sprayed from the emitter onto the collector and focused by the voltage difference between the emitter and the collector. The maximum concentration of the polymer solution that can be spun can depend on the viscosity and conductivity of the polymer and can also be varied by different base / functional polymers or different solvents. After a successful initial fiber formation, the x-axis translation stage of the emitter can be set in a repeating linear pattern. The fibers can be collected on a rotating drum collector. The fibers can also be collected on a flat surface. The fibers can further be collected in the form of a membrane by collecting the fibers on a patterned structure. The resulting membrane can include a shape that is the same shape as the patterned structure.
[0107]
[0113] Membranes (e.g., electrospun polymer membranes) are made from individual fibers that are spun onto a structure, such as a rotating drum collector or patterned structure. These individual fibers can have diameters of 180 nm to 240 nm, 520 nm to 560 nm, or even less than 1000 nm. Individual fibers are available in sizes ranging from 100nm to 120nm, 120nm to 140nm, 140nm to 160nm, 160nm to 180nm, 180nm to 200nm, 200nm to 220nm, 220nm to 240nm, 240nm to 260nm, 260nm to 280nm, 280nm to 300nm, 300nm to 320nm, 320nm to 340nm, 340nm to 360nm, 360nm to 380nm, 380nm to 400nm, 400nm to 420nm, 420nm to 440nm, 440nm to 460nm, 460nm to 480nm, 480nm to 500nm, 500nm to 520nm, 520nm to 540nm, 540nm to 560nm, 570nm to 580nm, 590nm to 600nm, 610nm to 620nm, 620nm to 630nm, 630nm to 640nm, 640nm to 650nm, 650nm to 660nm, 660nm to 670nm, 670nm to 680nm, 680nm to 700nm, 680nm to 710nm, 680nm to 720nm, 690nm to 730nm, 740nm to 750nm, 750nm to 760nm, 760nm to 770nm, 780nm to 790nm, 790nm to 800nm, 790nm to 810nm nm, 560nm~580nm, 580nm~600nm, 600nm~620nm, 620nm~640nm, 640nm~660nm, 660nm~680nm, 680nm~700nm, 700nm~720nm, 720nm~740nm, 740nm~760nm, 760nm~780nm, 780nm~800nm, 800nm~820nm, 820nm~840nm, 840nm~860nm, 860nm~880nm, 880nm~900nm, 900nm~920nm, 920nm~940nm, 940nm~960nm, 960nm~980nm, 980nm~1000nm.
[0108]
[0114] The diameter of the fibers can be important with respect to the functional properties of the membrane (e.g., electrospun polymer membrane). For example, as shown in FIG. 1B, increasing the diameter of the individual fibers can increase the diffusion of the encapsulated moiety from the membrane (e.g., electrospun polymer membrane), for example, by decreasing the porosity of the membrane. FIG. 1A shows a membrane (e.g., electrospun polymer membrane) with different sizes of individual fiber diameters, which can be obtained by adjusting the concentration of the polymer solution prior to electrospinning and by adjusting the voltage. As further shown in FIG. 2A and FIG. 2B, increasing the fiber diameter to 540 nm (FIG. 2A) resulted in an increase in the release of both the 4 kDa and 500 kDa moieties, while decreasing the fiber diameter decreased the release of both the 4 kDa and 500 kDa moieties. The reduction in the diameter of the individual fibers in the electrospun membrane can allow an increase in the overall packing of the polymer matrix and the interconnecting fiber filaments, which can result in a concomitant increase in the porous tortuosity of the membrane microstructure. This increased tortuosity may decrease the release of any drug incorporated into the membrane. Thus, in designing the membranes (e.g., electrospun polymer membranes) of the present disclosure, the diameters can be varied to precisely tune the desired release profile of the different molecular weight moieties. For example, a rapid release of the low flow molecular weight moieties can be achieved by increasing the fiber diameter. Alternatively, a slower release of the low flow molecular weight moieties can be achieved by decreasing the fiber diameter. The fiber filament diameter can be increased or decreased by adjusting one or more of several electrospinning parameters, including, but not limited to, the polymer concentration in the electrospinning solution (e.g., percent (w / v) polymer in the electrospinning solution), the positive voltage, the negative voltage, the feed rate (mL / h), the distance of the needle from the fiber collector, and the time of electrospinning. Each of these parameters can be adjusted individually or in combination with any other parameter to change the fiber filament diameter.For example, the polymer concentration in the electrospinning solution can be adjusted from as low as 0.01 wt% to as high as 10 wt%, from 6 wt% to 8 wt%, or from 8 wt% to 10 wt%, as a parameter for varying the fiber filament diameter. The positive voltage can be adjusted from 10 to 30 or from 20 to 22 as a parameter for varying the fiber filament diameter. The negative voltage can be adjusted from 1 to 10 or held at 5 to vary the fiber filament diameter. The feed rate can be adjusted from 0.1 to 5 mL / h or from 0.7 to 1.25 mL / h to vary the fiber filament diameter. The needle-to-collector distance can be adjusted from 0.1 to 30 cm to vary the fiber filament diameter, or held constant at about 17.5 cm. The electrospinning time can be adjusted from 30 minutes to 504 minutes to vary the fiber filament diameter, or can include spinning times of 30 minutes to 60 minutes, 60 minutes to 120 minutes, 36 minutes to 72 minutes, 72 minutes to 144 minutes, 144 minutes to 252 minutes, or 252 minutes to 504 minutes.
[0109]
[0115] Once electrospinning is complete and / or crosslinking is complete, the membrane can have a thickness of 10 μm to 150 μm or 80 μm to 120 μm. In some cases, the membrane (e.g., electrospun polymer membrane) can have a thickness of 10 μm to 500 μm. For example, the membrane (e.g., electrospun polymer membrane) may have a thickness of 10 μm to 20 μm, 20 μm to 30 μm, 30 μm to 40 μm, 40 μm to 50 μm, 50 μm to 60 μm, 60 μm to 70 μm, 70 μm to 80 μm, 80 μm to 90 μm, 90 μm to 100 μm, 100 μm to 110 μm, 110 μm to 120 μm, 120 μm to 130 μm, 130 μm to 140 μm, 140 μm to 150 μm, 150 μm to 160 μm, 160 μm to 170 μm, 170 μm to 180 μm, 180 μm to 190 μm , 190μm~200μm, 200μm~210μm, 210μm~220μm, 220μm~230μm, 230μm~240μm, 240μm~250μm, 250μm~260μm, 260μm~270μm, 270μm~280μm, 2 80μm~290μm, 290μm~300μm, 300μm~310μm, 310μm~320μm, 320μm~330μm, 330μm~340μm, 340μm~350μm, 350μm~360μm, 360μm~370μm, 370 The thickness of the membrane (e.g., electrospun polymer membrane) can be used to adjust the release rate of the encapsulated drug. For example, by increasing the thickness of the membrane, the encapsulated drug can have a longer distance to traverse before exiting the polymer membrane. Thus, increasing the thickness of the membrane can be another way to attenuate the rapid burst release of the drug from the membrane. Furthermore, increasing the thickness of the membrane (e.g., electrospun polymer membrane) can also result in a membrane that is bulkier and has better long-term mechanical strength. Increasing the thickness alone can also reduce the flux of incorporated drugs from the resulting membrane. The membranes (e.g., electrospun polymer membranes) of the present disclosure can be hydrophilic. Hydrophilicity can be important in one aspect of the present invention to prevent dewetting of the membrane surface to maintain continuous solute diffusion. In other aspects of the present disclosure, the membranes (e.g., electrospun polymer membranes) described herein can also be hydrophobic.
[0110]
[0116] The membrane (e.g., electrospun polymer membrane) can include a functional polymer, which is subsequently crosslinked to obtain a crosslinked functional membrane (e.g., electrospun polymer membrane). A crosslinking agent and / or crosslinking initiator, as described further below, can be included in the initial polymer solution. A crosslinking agent and / or crosslinking initiator, as described further below, can also be incorporated by exposing the membrane (e.g., electrospun polymer membrane) to a solution of the crosslinking agent, followed by exposing the membrane (e.g., electrospun polymer membrane) to a crosslinking method. A crosslinked functional membrane (e.g., electrospun polymer membrane) can then be obtained using these electrospinning and crosslinking synthesis strategies. For example, the crosslinking agent, TEGDA, can be dissolved with PAN and PEGMA in a solvent and then electrospun to produce a PAN / PEGMA / TEGDA membrane. This PAN / PEGMA / TEGDA membrane can then be immersed in a solution that can contain only a photoinitiator and further exposed to UV light for crosslinking, resulting in a crosslinked PAN / PEGMA / TEGDA membrane. Alternatively, PAN and PEGMA can be dissolved in a solvent and electrospun to produce a PAN / PEGMA membrane. The electrospun membrane is immersed in a solution that can contain a crosslinker (e.g., TEGDA) and a photoinitiator. The membrane is then exposed to UV light to form a crosslinked PAN / PEGMA / TEGDA membrane. Crosslinked functional membranes (e.g., electrospun polymer membranes) are also described herein as having a "coating" or "overcoating". The membranes (e.g., electrospun polymer membranes) of the present disclosure can also be uncrosslinked and thus obtained without a coating.
[0111]
[0117] The membrane (e.g., electrospun polymer membrane) (e.g., whether crosslinked or not) can be designed to allow the passage of cells. For example, the membrane (e.g., electrospun polymer membrane) before or after crosslinking can be designed to have a pore size of about 5 μm or more. The membrane (e.g., electrospun polymer membrane) can also be designed to block the passage of cells. For example, the membrane (e.g., electrospun polymer membrane) before or after crosslinking can be designed to have a pore size of about 3 μm or more. The pore size of the membrane (e.g., electrospun polymer membrane) can be anywhere between 10 nm and 10 μm. For example, the pore size is 10nm~50nm, 50nm~100nm, 100nm~150nm, 150nm~200nm, 200nm~250nm, 2 50nm~300nm, 300nm~350nm, 350nm~400nm, 400nm~450nm, 450nm~500nm, 500nm~55 0nm, 550nm~600nm, 600nm~650nm, 650nm~700nm, 700nm~750nm, 750nm~800nm, 800 nm~850nm, 850nm~900nm, 900nm~950nm, 950nm~1μm, 1μm~2μm, 2μm~3μm, 3μm~4μm, It can be 4 μm to 5 μm, 5 μm to 6 μm, 6 μm to 7 μm, 7 μm to 8 μm, 8 μm to 9 μm, 9 μm to 10 μm. In some cases, a membrane with a pore size of 5 μm or less can result in restricted passage of cells, and an increase in pore size can increase the entry or escape of cells.
[0112]
[0118] The membranes (e.g., electrospun polymer membranes) of the present disclosure (e.g., whether crosslinked or not) can have excellent mechanical properties that allow them to be implanted in a subject for extended periods of time without losing structural integrity. These membranes can be engineered to obtain a particular tensile strength or Young's modulus. For example, the tensile strength of the membranes (e.g., electrospun polymer membranes) of the present disclosure can be about 1 MPa or greater. The tensile strength of the membranes (e.g., electrospun polymer membranes) of the present disclosure can be 0.5 MPa to 1 MPa, 1 MPa to 1.5 MPa, 1.5 MPa to 2 MPa, 2 MPa to 2.5 MPa, 2.5 MPa to 3 MPa, 3 MPa to 3.5 MPa, 3.5 MPa to 4 MPa, 4 MPa to 4.5 MPa, 4.5 MPa to 5 MPa, 5 MPa to 5.5 MPa, 5.5 MPa to 6 MPa, 6 MPa to 6.5 MPa, 6.5 MPa to 7 MPa, 7 MPa to The Young's modulus of the membrane of the present disclosure (e.g., electrospun polymer membrane) can be about 30 MPa or more. The Young's modulus of the membrane of the present disclosure (e.g., electrospun polymer membrane) can be 10 MPa to 100 MPa.For example, Young's modulus is 10MPa to 15MPa, 15MPa to 20MPa, 20MPa to 25MPa, 25MPa to 30MPa, 30MPa to 35MPa, 35MPa to 40MPa, 40MPa to 45MPa, 45MPa to 50MPa, 50MPa to 55MPa, 55MPa to 60MPa, 60MPa to 65MPa, 65MPa to 70MPa, 70MPa to 75MPa, 75MPa to 80MPa, 80MPa to 85 ... 5MPa~90MPa, 90MPa~95MPa, 95MPa~100MPa, 100MPa~150MPa, 150MPa~200MPa, 200MPa~250MPa, 250MPa~300MPa, 300M Pa~350MPa, 350MPa~400MPa, 400MPa~450MPa, 450MPa~500MPa, 500MPa~600MPa, 600MPa~700MPa, 700MPa~800MPa, 80 0MPa~900MPa, 900MPa~1,000MPa, 1,000MPa~2,000MPa, 2,000MPa~3,000MPa, 3,000MPa~4,000MPa, 4,000MPa~5,00 0MPa, 5,000MPa~6,000MPa, 6,000MPa~7,000MPa, 7,000MPa~8,000MPa, 8,000MPa~9,000MPa, 9,000MPa~10,000MPa, It can be 10,000MPa to 20,000MPa, 20,000MPa to 30,000MPa, 30,000MPa to 40,000MPa, 40,000MPa to 50,000MPa, 50,000MPa to 60,000MPa, 60,000MPa to 70,000MPa, 70,000MPa to 80,000MPa, 80,000MPa to 90,000MPa or 90,000MPa to 100,000MPa.
[0113] crosslinking technology
[0119] Various crosslinking methods can be utilized to obtain the functional crosslinked membranes (e.g., electrospun polymer membranes) of the present disclosure. These methods include, but are not limited to, UV crosslinking with photoinitiators, thermal crosslinking with thermal crosslinking initiators, transition metal and other chemical crosslinking methods. Crosslinkers can include polymeric crosslinkers or other molecular structures that can be used in one of the crosslinking reactions described below to form new bonds between reactive groups on the functional polymers. In other words, crosslinkers can be used to chemically link reactive groups on the functional polymers in the membranes (e.g., electrospun polymer membranes) of the present disclosure. This is a promising method for crosslinking the functional polymers in a wide range of applications. This can result in improved mechanical properties, better device integrity, control of the porosity and therefore the diffusion rates of different molecular weight moieties through the membrane (eg, electrospun polymer membrane).
[0114]
[0120] The crosslinker can include any functional polymer or other chemical moiety as described above. For example, the crosslinker can be a functional issue and can include, but is not limited to, polyethylene glycol (PEG), poly(ethylene glycol) methacylate (PEGMA), poly(ethylene glycol) diacylate (PEGDA), tetraethylene glycol diacrylate (TEGDA), or any combination thereof.Crosslinkers include bis(2-(succinimidyl-oxycarbonyloxyl)ethyl)sulfone, di(n-succinimidyl)glutarate, disuccinimidyl tartrate, 3,3'-dithiobis(sulfosuccinimidyl)propionate, p-phenylenediisothiocyanate, sebacic acid bis(N-succinimidyl)ester, suberic acid bis(N-hydroxysuccinimide ester), APN-CHO, bromoacetic acid N-hydroxysuccinimide ester, CBTF, iodoacetic acid N-hydroxysuccinimide ester, maleimido-PEG-succinimidyl ester, maleimidoacetic acid N-hydroxysuccinimide ester, adipic acid dihydrazide, alkyne-PEG-maleimide, APN-amine, APN-azide, APN-BCN, APN-COCl, and biotin-benzyl-tetrazine. , Biotin-PEG-TPG, 1,11-Diazido-3,6,9-trioxaundecane, Dibenzocyclooctyne-N-hydroxysuccinimidyl ester, Dibenzocyclooctyne-maleimide, Dibenzocyclooctyne-PEG-maleimide, 4-(maleimido)phenylisocyanate (approximately 95% pure), 4,4'-methylenebis(phenylisocyanate), 3-(2-pyridyldithio)propionylhydrazide, Propargyl-N-hydroxylsuccinimidyl ester, PTAD-azide, Sulfo-NHS-diazirine, Sulfosuccinimidyl 4,4'-azipentanoate, 4-(N-maleimido)benzophenone, 4-Azidophenacyl bromide, 5-Azido-2-nitrobenzoic acid N-hydroxysuccinimidyl ester acid N-hydroxy succinimide ester), succinimidyl-[4-(psoralen-8-yloxy)]butyrate, 4-benzoylbenzoic acid N-succinimidyl ester, 1,4-bis[3-(2-pyridyldithio)propionamido]butane, bis-maleimidoethane, dithio-bis-maleimidoethane, and the like.
[0115]
[0121] The crosslinking agent can be present at 2% (w / v) or 7% (w / v). In some cases, the crosslinking agent can be present at 0.01% (w / v), 0.1% (w / v), 0.5% (w / v), 1% (w / v), 10% (w / v), or 20% (w / v). In some cases, the crosslinking agent can be present at about 0.01% (w / v) to about 20% (w / v), 0.01% (w / v) to about 0.05% (w / v), 0.05% (w / v) to about 0.1% (w / v), 0.1% (w / v) to about 0.2% (w / v), 0.2% (w / v) to about 0.3% (w / v), 0.3% (w / v) to about 0.4% (w / v), or 0.4% (w / v) to about 0.5% (w / v). It may be present at about 0.5% (w / v) to about 1% (w / v), 1% (w / v) to about 2% (w / v), 2% (w / v) to about 3% (w / v), 3% (w / v) to about 4% (w / v), 4% (w / v) to about 5% (w / v), 5% (w / v) to about 10% (w / v), 10% (w / v) to about 15% (w / v), or 15% (w / v) to about 20% (w / v).
[0116]
[0122] UV Photoinitiators. Ultraviolet (UV) photoinitiators can be utilized to crosslink the functional membranes (e.g., electrospun polymer membranes) of the present disclosure. Photoinitiators can be used to catalyze crosslinking upon exposure to UV light. Photoinitiators can be incorporated into the initial polymer solution, which is then electrospun into a functional membrane (e.g., electrospun polymer membrane) and placed under UV light to initiate crosslinking. Photoinitiators can be used to catalyze crosslinking upon exposure to UV light. Photoinitiators can also be incorporated by immersing a functionalized film (e.g., an electrospun polymer film) in a solution containing the photoinitiator. The functionalized film (e.g., an electrospun polymer film) is then dried and placed under UV light to initiate crosslinking. Suitable photoinitiators that are compatible with the present disclosure and can be incorporated into a functional film (e.g., an electrospun polymer film) include acetophenone, anisoin, anthraquinone, benzil, benzoin, benzenetricarbonylchromium, benzoin ethyl ether, benzoin isobutyl ether, benzoin methyl ether, benzophenone, 3,3',4,4'-benzophenonetetracarboxylic dianhydride, 4-benzoylbiphenyl, 2-benzyl-2-(dimethylamino)-4'-morpholinobutyrophenone, 4,4'-bis(diethylamino)benzophenone, camphorquinone, 2-chlorothioxanthen-9-one, (cumene)cyclopentadienyliron(II) hexafluorophosphate, dibenzosuberenone, 2,2-diethoxyacetophenone, 4,4'-dihydroxybenzophenone, 2,2-dimethoxy-2-phenylacetophenone, 4-(dimethylamino)benzophenone, 4,4'-dimethylbenzyl, 2,5-dimethyl ... Non(2,5-dimethylbenzonphenone), 3,4-dimethylbenzophenone, diphenyl(2,4,6-trimethylbenzoyl)phosphine oxide, 4'-ethoxyacetophenone, 2-ethylanthraquinone, ferrocene, 3-hydroxyacetophenone, 4-hydroxyacetophenone, 1-hydroxycyclohexyl phenyl ketone, 2-hydroxy-2-methylpropiophenone, 2-methylbenzophenone, 3-methylbenzophenone, methylbenzoyl formate, 2-methyl-4'-(methylthio)-2-morpholinopropiophenone, phenanthrenequinone, 4'-phenoxyacetophenone, thioxanthen-9-one, triarylsulfonium, hexafluoroantimonate salts, triarylsulfonium hexafluorophosphate salts, and the like.
[0117]
[0123] Figure 8A shows a schematic diagram of an exemplary crosslinked functional electrospun polymer membrane of the present disclosure made by UV crosslinking. PEGMA (functional polymer) or PEGMA and TEGDA (functional polymer and crosslinker polymer) can be incorporated into a membrane (e.g., an electrospun polymer membrane) and exposed to a photoinitiator and UV light to crosslink the electrospun polymer device. Figure 8B further confirms that upon UV crosslinking, the carbon-carbon double bonds are converted to carbon-carbon single bonds, thereby demonstrating successful crosslinking of the functional polymer.
[0118]
[0124] Another example of a crosslinked functional membrane (e.g., electrospun polymer membrane) comprising PAN and PEGMA is shown in FIG. 7. FIG. 7A shows the membrane (e.g., electrospun polymer membrane) before UV crosslinking, and FIG. 7B shows the membrane (e.g., electrospun polymer membrane) after crosslinking with TEGDA crosslinker. As can be seen from a comparison of FIG. 7A and FIG. 7B, after UV crosslinking, the porosity of the polymer membrane is reduced and the polymer appears more webbed. FIG. 7C demonstrates the modulation of the release of 4 kDa FITC-dextran molecules (representing insulin) from a PAN / PEGMA membrane (e.g., electrospun polymer membrane) at different ratios of base polymer to functional polymer and in the presence of TEGDA. This figure shows that the UV crosslinking method described above can be effectively used to attenuate the burst release of the encapsulated drug. Thus, the desired flux of the low molecular weight therapeutic moiety (e.g., the desired D of the low molecular weight therapeutic moiety) can be controlled by the UV crosslinking method. first ) UV-based crosslinking of functional electrospun polymers can be achieved by D first can be used to adjust
[0119]
[0125] 9A and 9B illustrate some of the improvements in mechanical strength and device integrity imparted by UV-based crosslinking of functional membranes (e.g., electrospun polymer membranes). As shown in these figures, the inclusion of a crosslinker such as TEGDA FIG. 9C further illustrates the release of low molecular weight therapeutic moieties (e.g., a desired D of low molecular weight therapeutic moieties) from crosslinked functional membranes (e.g., electrospun polymer membranes) herein. first ) regulation. This figure is based on the first FIG. 1 illustrates that an overall reduction in modulus can be achieved by UV-based crosslinking.
[0120]
[0126] Thermal initiators. Thermal initiators can be utilized to crosslink the functional membranes (e.g., electrospun polymer membranes) of the present disclosure. Thermal initiators can be used to catalyze crosslinking upon exposure to heat. The temperature used in the present disclosure to catalyze thermally mediated crosslinking can be 40°C to 100°C. The temperature used in the present disclosure to catalyze thermally mediated crosslinking can be 40°C to 45°C, 45°C to 50°C, 50°C to 55°C, 55°C to 60°C, 60°C to 65°C, 65°C to 70°C, 70°C to 75°C, 75°C to 80°C, 80°C to 85°C, 85°C to 90°C, 90°C to 95°C, or 95°C to 100°C. Thermal initiators can be incorporated into the initial polymer solution, which is then electrospun into a functional membrane (e.g., electrospun polymer membrane) and heated to initiate crosslinking. Thermal initiators can also be incorporated by immersing a functionalized film (e.g., an electrospun polymer film) in a solution containing a photoinitiator. The functionalized film (e.g., an electrospun polymer film) is then dried and placed under UV light to initiate crosslinking.
[0121]
[0127] Suitable thermal initiators that are compatible with the present disclosure and that can be incorporated into a functional film (e.g., an electrospun polymer film) include ammonium persulfate, tert-amylperoxybenzoate, 4,4-azobis(4-cyanovaleric acid), 1,1′-azobis(cyclohexanecarbonitrile), 2,2′-azobisisobutyronitrile, benzoyl peroxide, 2,2′-bis(tert-butylperoxy)butane, 1,1-bis(tert-butylperoxy)cyclohexane, 2,5-bis(tert-butylperoxy)-2,5-dimethyl ... tert-butylperoxy)-2,5-dimethyl-3-hexyne, bis(1-(tert-butylperoxy)-1-methylethyl)benzene, 1,1-bis(tert-butylperoxy)-3,3,5-trimethylcyclohexane, tert-butyl hydroperoxide, tert-butyl peracetate, tert-butyl peroxide, tert-butyl peroxybenzoate, tert-butylperoxyisopropyl carbonate, cumene, hydroperoxide, cyclohexanone peroxide, dicumyl peroxide, lauroyl peroxide, 2,4-pentanedione peroxide, peracetic acid, potassium persulfate, and the like.
[0122]
[0128] Transition metals. Transition metals can be utilized to crosslink the functional membranes (e.g., electrospun polymer membranes) of the present disclosure. The transition metals can interact with reactive groups on the functional polymer to regulate the crosslinking of the functional membrane (e.g., electrospun polymer membrane). The transition metals can be incorporated by initiating immersion of the functional membrane (e.g., electrospun polymer membrane) in a solution. Suitable transition metals that are compatible with the present disclosure and can be incorporated into the functional membrane (e.g., electrospun polymer membrane) include, but are not limited to, ions of beryllium, magnesium, calcium, barium, manganese, copper, iron, and the like.
[0123] Diffusion rate
[0129] The present disclosure relates to a first diffusion coefficient (D first ) and the second diffusion coefficient (D secondTo provide a membrane (e.g., an electrospun polymer membrane) that can be characterized by the ratio of D first and D. second corresponds to a first moiety having a first molecular weight and a second moiety having a second molecular weight portion. In some cases, the first moiety can be a moiety (e.g., a therapeutic moiety) that is disposed or contained within the membrane. It can be desirable to be able to provide for effective release or diffusion of the first moiety from or across the membrane. In some cases, the second moiety can be a moiety that is located or contained on the outside of the membrane (e.g., inside the host's body). It can be desirable to be able to prevent or stop diffusion of the second moiety into or across the membrane. As an example, the first moiety can be insulin and the second moiety can be IgG.
[0124]
[0130] The first molecular weight portion can have a molecular weight of between 100 Da and 100,000 Da. In some cases, the first molecular weight portion can have a molecular weight of about 50 Da, 100 Da, 200 Da, 400 Da, 600 Da, 800 Da, 1000 Da, 1500 Da, 2000 Da, 2500 Da, 3000 Da, 3500 Da, 4000 Da, 5000 Da, 6000 Da, 7000 Da, 8000 Da, 9000 Da, 10000 Da, 12000 Da, 14000 Da, 16000 Da, 18000 Da, 20 ...500 Da, 4000 Da, 5000 Da, 6000 Da, 7000 Da, 8000 Da, 9000 Da, 10000 Da, 12000 Da, 14000 It may have a molecular weight of less than or equal to 0 Da, 30000 Da, 35000 Da, 40000 Da, 45000 Da, 50000 Da, 55000 Da, 60000 Da, 65000 Da, 70000 Da, 75000 Da, 80000 Da, 85000 Da, 90000 Da, 95000 Da, 100000 Da, 110000 Da, 120000 Da, 130000 Da, 140000 Da or 150000 Da. In some cases, the first molecular weight portion is about 50 Da, 100 Da, 200 Da, 400 Da, 600 Da, 800 Da, 1000 Da, 1500 Da, 2000 Da, 2500 Da, 3000 Da, 3500 Da, 4000 Da, 5000 Da, 6000 Da, 7000 Da, 8000 Da, 9000 Da, 10000 Da, 12000 Da, 14000 Da, 16000 Da, 18000 Da, 20 ...500 Da, 4000 Da, 5000 Da, 6000 Da, 7000 Da, 8000 Da, 9000 Da, 10000 Da, 12000 Da, 14000 Da, 16000 Da, 18000 Da, 20000 Da, 2500 Da, It may have a molecular weight of 0 Da, 30000 Da, 35000 Da, 40000 Da, 45000 Da, 50000 Da, 55000 Da, 60000 Da, 65000 Da, 70000 Da, 75000 Da, 80000 Da, 85000 Da, 90000 Da, 95000 Da, 100000 Da, 110000 Da, 120000 Da, 130000 Da, 140000 Da or 150000 Da or more.In some cases, the first molecular weight portion can have a molecular weight between any of the following values: 50 Da, 100 Da, 200 Da, 400 Da, 600 Da, 800 Da, 1000 Da, 1500 Da, 2000 Da, 2500 Da, 3000 Da, 3500 Da, 4000 Da, 5000 Da, 6000 Da, 7000 Da, 8000 Da, 9000 Da, 10000 Da, 12000 Da, 14000 Da, 16000 Da. , 18000Da, 20000Da, 25000Da, 30000Da, 35000Da, 40000Da, 45000Da, 50000Da, 55000Da, 60000Da, 65000Da, 70000Da, 75000Da, 80000Da, 85000Da, 90000Da, 95000Da, 100000Da, 110000Da, 120000Da, 130000Da, 140000Da or 150000Da.
[0125]
[0131] The second molecular weight portion can have a molecular weight of 50,000 Da to 1,000,000 Da. In some cases, the second molecular weight portion can have a molecular weight of about 50,000 Da, 75,000 Da, 100,000 Da, 120,000 Da, 140,000 Da, 160,000 Da, 180,000 Da, 200,000 Da, 250,000 Da, 300,000 Da, 350,000 Da, 400,000 Da, 450,000 Da, 500,000 Da, 600,000 Da, 700,000 Da, 800,000 Da, 900,000 Da, or 1,000,000 Da or less. In some cases, the second molecular weight portion can have a molecular weight of about 50,000 Da, 75,000 Da, 100,000 Da, 120,000 Da, 140,000 Da, 160,000 Da, 180,000 Da, 200,000 Da, 250,000 Da, 300,000 Da, 350,000 Da, 400,000 Da, 450,000 Da, 500,000 Da, 600,000 Da, 700,000 Da, 800,000 Da, 900,000 Da, or 1,000,000 Da. In some cases, the second molecular weight portion can have a molecular weight between any of the following values: 50,000 Da, 75,000 Da, 100,000 Da, 120,000 Da, 140,000 Da, 160,000 Da, 180,000 Da, 2 00000Da, 250000Da, 300000Da, 350000Da, 400000Da, 450000Da, 500000Da, 600000Da, 700000Da, 800000Da, 900000Da or 1000000Da.
[0126]
[0132] The ratio of the molecular weight of the second molecular weight portion to the molecular weight of the first molecular weight portion can be in the range of 1 to 100. In some cases, the ratio of the molecular weight of the second molecular weight portion to the molecular weight of the first molecular weight portion can be greater than or equal to about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 14, 16, 18, 20, 24, 26, 28, 30, 35, 40, 45, 50, 60, 70, 80, 90, or 100. In some cases, the ratio of the molecular weight of the second molecular weight portion to the molecular weight of the first molecular weight portion can be less than or equal to about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 14, 16, 18, 20, 24, 26, 28, 30, 35, 40, 45, 50, 60, 70, 80, 90, or 100. In some cases, the ratio of the molecular weight of the second molecular weight portion to the molecular weight of the first molecular weight portion can be within any of the following values: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 14, 16, 18, 20, 24, 26, 28, 30, 35, 40, 45, 50, 60, 70, 80, 90 or 100.
[0127]
[0133] The ratio of the molecular weight of the second molecular weight portion to the molecular weight of the first molecular weight portion can be about 10 or more. The ratio of the molecular weight of the second molecular weight portion to the molecular weight of the first molecular weight portion can be about 20 or more. The ratio of the molecular weight of the second molecular weight portion to the molecular weight of the first molecular weight portion can be about 30 or more. The first molecular weight portion can be less than about 10 kDa. The second molecular weight portion can be greater than about 100 kDa. In an exemplary embodiment of the present disclosure, the first molecular weight portion can be equal to about 4 kDa and the second molecular weight portion can be equal to about 150 kDa.
[0128]
[0134] The membrane (e.g., electrospun polymer membrane) may have a D of about 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 35, 40, or 50 or more. first / D second For example, high D first / D second A membrane (e.g., electrospun polymer membrane) with a ratio (high-flux electrospun polymer membrane) is shown in FIG. 3A. This figure compares commercially available membranes and other membrane blends with a high-flux membrane (e.g., electrospun polymer membrane) that is not crosslinked. The high-flux membrane (e.g., electrospun polymer membrane) has a ratio of about 8.5×10 7 cm 2 D / sec first (D 4kDa ) and approximately 2 × 10 7 Dcm 2 D / sec second (D 150kDa In this example, D first / D second The ratio was about four.
[0129]
[0135] D first is 10 -7 cm 2 / sec or more, which may correspond to the diffusion coefficient for insulin. second may correspond to the diffusion coefficient for IgG. D of the membrane (e.g., electrospun polymer membrane) first / D second The ratio can be imparted by crosslinking a functional membrane (e.g., an electrospun polymer membrane). first / D second Ratios may characterize any membrane (e.g., electrospun polymer membrane) of the present disclosure. For example, D first / D second The ratio can also characterize non-crosslinked membranes (e.g., electrospun polymer membranes). first / D secondThe ratio can be controlled by a variety of techniques presented herein, including varying the molecular weight of the base polymer(s), varying the molecular weight of the functional polymer(s), selecting a particular base polymer and / or functional polymer that has increased or decreased interaction with the first and second moieties, altering the pore size of the membrane (e.g., electrospun polymer membrane), altering the diameter of the individual fibers in the membrane (e.g., electrospun polymer membrane), amount of crosslinker, time of crosslinking, and other variables.
[0130]
[0136] D of the membranes (e.g., electrospun polymer membranes) of the present disclosure first / D second ratio can be designed based on the desired application. For example, a membrane (e.g., an electrospun polymer membrane) including a crosslinked functional membrane (e.g., an electrospun polymer membrane) can be designed for long-term insulin delivery to a subject for transplantation purposes and for treating diabetes. In this example, the crosslinked functional membrane (e.g., an electrospun polymer membrane) can be designed to encapsulate engineered stem cells that secrete insulin. Thus, the crosslinked functional membrane (e.g., an electrospun polymer membrane) can be designed to encapsulate engineered stem cells that secrete insulin (D) from the membrane. first ) and encapsulation of cells (D) by selecting a specific polymer, crosslinker, crosslinker concentration, crosslinking time, membrane porosity, fiber diameter, or any combination thereof. second ) or the host part (D second ), such as host cells or host proteins, or any combination thereof. In another example, a crosslinked functional membrane (e.g., an electrospun polymer membrane) can be designed to initially encapsulate insulin, where the crosslinked functional membrane (e.g., an electrospun polymer membrane) allows for a high flux (D) of insulin through the membrane. first ) while providing diffusion of host cells or host moieties such as host proteins (D second ) can be designed to limit
[0131] Therapeutic Agents
[0137] The membranes (e.g., electrospun polymer membranes) disclosed herein, whether crosslinked or not, can be loaded with a therapeutic agent. The therapeutic agents of the present disclosure can include moieties that exhibit either indirect or direct therapeutic benefit. Therapeutic agents can be embedded in the membrane (e.g., electrospun polymer membranes) by incorporation into an initial polymer solution, which is then electrospun into a functional membrane (e.g., electrospun polymer membrane). Therapeutic agents can also be incorporated by immersing a crosslinked functional membrane (e.g., electrospun polymer membrane) in a solution containing the therapeutic agent.
[0132]
[0138] Cells. Therapeutic agents that confer indirect therapeutic benefits can include cells, such as cells engineered to secrete drugs with therapeutic benefits. For example, the cells can be engineered to produce insulin. For example, the cells can be stem cell-derived beta islet cells engineered to express insulin. After being incorporated into a crosslinked functional membrane (e.g., an electrospun polymer membrane), the cells secrete insulin after implantation of the membrane in a subject. In some cases, the cells can be a population of non-native pancreatic beta cells. The cells can be stem cell-derived islet cells that contain several types of cells: alpha-2 cells, which produce the hormone glucagon; beta cells, which manufacture the hormone insulin (also referred to herein as "pancreatic beta cells"); and alpha-1 cells, which produce the regulatory factor somatostatin.
[0133]
[0139] The cells can be mature cells. The cells can exhibit an in vitro glucose stimulated insulin secretion (GSIS) response. The cells can exhibit an in vivo GSIS response. The cells can exhibit an in vitro glucose stimulated insulin secretion (GSIS) response. The cells can exhibit an in vitro and in vivo glucose stimulated insulin secretion (GSIS) response. The cells can exhibit a GSIS response to at least one glucose load. The cells can exhibit a GSIS response to at least two consecutive glucose loads. The cells can exhibit a GSIS response to at least three consecutive glucose loads. The GSIS response can be observed immediately upon implantation of the cells into a human or animal. The GSIS response can be observed within approximately 24 hours of implantation of the cells into a human or animal. The GSIS response can be observed within approximately two weeks of implantation of the cells into a human or animal.
[0134]
[0140] The cell can be a stem cell-derived beta cell. The cell can be a non-native pancreatic beta cell. The stem cell-derived beta cell can be non-native. As used herein, "non-native" refers to the difference between the cell and a cell that occurs in nature (e.g., a native beta cell). By significantly different, we mean different in some aspect (e.g., gene expression profile). For example, non-native pancreatic beta cells may not express somatostatin, glucagon, or both.
[0135]
[0141] It is a) a hormone selected from the group consisting of i) glucagon (GCG) and ii) somatostatin (SST); b) an acinar cell marker selected from the group consisting of i) amylase and ii) carboxypeptase A (CPA1); d) an alpha cell marker selected from the group consisting of i) CFTR and ii) Sox9; and d) an alpha cell marker selected from the group consisting of Irx, Irx1, and Irx2; The cell may not express at least one marker selected from the starting cells (e.g., markers not expressed by endogenous mature pancreatic β cells). The present invention is not intended to be limited by the starting cells from which the cells are derived, so the cells can be differentiated in vitro from any starting cells. Exemplary starting cells include, but are not limited to, insulin-positive endocrine cells or any precursors thereof, such as Nkx6-1 positive pancreatic progenitor cells, Pdx1 positive pancreatic progenitor cells, and pluripotent stem cells, embryonic stem cells, and induced pluripotent stem cells. The cell can be differentiated in vitro from a reprogrammed cell, a partially reprogrammed cell (i.e., a fibroblast that is partially reprogrammed so that it exists in an intermediate state between a somatic cell, such as an induced pluripotent cell and the somatic cell from which it is derived), or a transdifferentiated cell. The cell can be differentiated in vitro from an insulin-positive endocrine cell or any precursors thereof. The cell can be differentiated in vitro from a progenitor cell selected from the group consisting of Nkx6-1 positive pancreatic progenitor cells, Pdx1 positive pancreatic progenitor cells and pluripotent stem cells.The pluripotent stem cell can be selected from the group consisting of embryonic stem cells and induced pluripotent stem cells.The cell or the pluripotent stem cell from which the cell is derived is a human cell.
[0136]
[0142] The cell can be an exocrine cell (e.g., a cell of an exocrine gland, i.e., a gland that releases its secretions through a duct). The cell can be a pancreatic cell, which can be a pancreatic cell that produces enzymes that are secreted into the small intestine. These enzymes can help digest food as it passes through the gastrointestinal tract. Pancreatic cells can secrete two hormones, insulin and glucagon. The pancreatic cell can be one of several cell types: an alpha-2 cell, which can produce the hormone glucagon; or a beta cell, which can manufacture the hormone insulin; and an alpha-1 cell, which can produce the regulator somatostatin. The non-insulin producing cell can be an alpha-2 cell or an alpha-1 cell. The pancreatic cell can be a pancreatic exocrine cell. The pancreatic cells can be pancreatic endocrine cells, which refers to pancreatic cells that produce hormones such as insulin (produced by beta cells), glucagon (produced by alpha-2 cells), somatostatin (produced by delta cells), and pancreatic polypeptide (produced by F cells) that are secreted into the bloodstream.
[0137]
[0143] The cells disclosed herein can be hormone-secreting cells.Hormonal secreting cells can be alpha cells, beta cells, adrenocorticotrophic cells, delta cells, gastric chief cells, gonadotropic cells, lactotrophic cells, parafollicular cells, parathyroid chief cells, somatolammotrophic cells, somatotropic cells or thyrotrophic cells.In one example, hormone-secreting cells can be stem cell-derived beta cells and / or insulin-secreting cells as described in Example 7.In another example, hormone-secreting cells can be parathyroid hormone-secreting cells as described in Example 13.
[0138]
[0144] Hormones secreted from cells are derived from amino acids (e.g. epinephrine). The hormones may be selected from the group consisting of thyrotropin, melatonin, triiodothyronine and thyroxine, eicosanoids (e.g. prostaglandins, leukotrienes, prostacyclin and therocis), peptide hormones (e.g. amylin, calcitonin, enkephalin, erythropoietin, galanin, glucagon, growth hormone, growth hormone releasing hormone, insulin, pancreatic polypeptide, parathyroid hormone, renin, somatostatin and vasoactive intestinal peptide) or steroids (e.g. androgens, estrogens, glucocorticoids, progestogens and secosteroids).
[0139]
[0145] The cell disclosed herein can be an enzyme-secreting cell. The enzyme-secreting cell can be a pancreatic cell. The enzyme-secreting cell can secrete proteases (e.g. trypsinogen and chymotrypsinogen), lipases, amylases, phospholipase A2, lysophospholipases or cholesterol esterases. The enzyme-secreting cell can also secrete proenzymes such as angiotensinogen, trypsinogen, chymotrypsinogen, pepsinogen, fibrinogen, procaspases, pacifastin, proelastase, prolipase and procarboxypolypeptidases.
[0140]
[0146] The cells were approximately 10 per μL of volume. 4 ~about 10 6 Cells can be encapsulated in a membrane (e.g., an electrospun polymer membrane), where the volume can refer to the luminal volume in the fabricated device. For example, the volume or luminal volume can be the amount of cell volume that the device can accommodate. In some cases, cells ... 6 ~Approx. 1×10 9 The cells can be encapsulated within a membrane (e.g., an electrospun polymer membrane). In some cases, the cells can be encapsulated within the membrane (e.g., an electrospun polymer membrane) at a concentration of about 4×10 cells per μL. 6 ~Approx. 5×10 6 , about 5×10 6 ~Approx. 6×10 6 , about 6×10 6~Approx. 7×10 6 , about 7×10 6 ~Approx. 8×10 6 , about 8×10 6 ~Approx. 9×10 6 , about 9×10 6 ~Approx. 1×10 7 , about 1×10 7 ~about 2×10 7 , about 2×10 7 ~Approx. 3×10 7 , about 3×10 7 ~Approx. 4×10 7 , about 4×10 7 ~Approx. 5×10 7 , about 5×10 7 ~Approx. 6×10 7 , about 6×10 7 ~Approx. 7×10 7 , about 7×10 7 ~Approx. 8×10 7 , about 8×10 7 ~Approx. 9×10 7 , about 9×10 7 ~Approx. 1×10 8 , about 1×10 8 ~about 2×10 8 , about 2×10 8 ~Approx. 3×10 8 , about 3×10 8 ~Approx. 4×10 8 , about 4×10 8 ~Approx. 5×10 8 , about 5×10 8 ~Approx. 6×10 8 , about 6×10 8 ~Approx. 7×10 8 , about 7×10 8 ~Approx. 8×10 8 , about 8×10 8 ~Approx. 9×10 8 or about 9 x 10 8 ~Approx. 1×10 9 It may be encapsulated in cells.
[0141]
[0147] Drugs. Therapeutic agents that confer direct therapeutic benefits can include drugs such as small molecules, peptides, proteins, or any combination thereof. These drugs can also be encapsulated as prodrugs, which are metabolized after release from the crosslinked functional membrane (e.g., electrospun polymer membrane) to their active therapeutic form. These drugs can include therapeutic agents of various physiochemical properties, including hydrophilic drugs, or any combination thereof. Hydrophobic drugs can be included in the initial polymer solution, which is subsequently electrospun. Hydrophilic drugs can be encapsulated in the formation of micronized microparticles or incorporated into the membrane (e.g., electrospun polymer membrane). Drugs can also be conjugated to reactive groups on the functional polymer using bioconjugation chemistry. Drugs can be dissolved or suspended in a solvent that is different but miscible with the solvent in which the polymer is dissolved prior to electrospinning. Drugs can also be dissolved or suspended in a solvent that is different and not miscible with the solvent in which the polymer is dissolved prior to electrospinning. Alternatively, drugs can be dissolved or suspended in the same solvent in which the polymer is dissolved prior to electrospinning.
[0142]
[0148] The drug may be from about 0.01 mg drug / mg polymer to about 0.5 mg drug / mg polymer, from about 0.01 mg drug / mg polymer to about 0.05 mg drug / mg polymer, from about 0.05 mg drug / mg polymer to about 0.1 mg drug / mg polymer, or from about 0.1 mg drug / mg The polymer can be present in the membrane (e.g., electrospun polymer membrane) at about 0.15 mg drug / mg polymer, about 0.15 mg drug / mg polymer to about 0.2 mg drug / mg polymer, about 0.2 mg drug / mg polymer to about 0.25 mg drug / mg polymer, about 0.25 mg drug / mg polymer to about 0.3 mg drug / mg polymer, about 0.3 mg drug / mg polymer to about 0.35 mg drug / mg polymer, about 0.35 mg drug / mg polymer to about 0.4 mg drug / mg polymer, about 0.4 mg drug / mg polymer to about 0.45 mg drug / mg polymer, or about 0.45 mg drug / mg polymer to about 0.5 mg drug / mg polymer. For example, the drug can be present in the membrane (e.g., electrospun polymer membrane) at about 0.01 mg drug / mg polymer to about 0.05 mg drug / mg polymer, or 0.05 mg drug / mg polymer to 0.1 mg drug / mg polymer. The drug can have a molecular weight of less than 10 kDa.The therapeutic agent of the present disclosure can include an antifibrotic agent, an anti-inflammatory agent, an angiogenesis promoter, a hydrophilizing agent, an antioxidant, a macrophage inhibitor, a cytotoxic drug, a chemotherapeutic drug, or any combination thereof.A specific therapeutic agent of the present disclosure can include insulin.
[0143]
[0149] In some embodiments, the drug comprises a recombinant growth factor, a cytokine, an anti-inflammatory agent, a targeted therapy, an adjunct, or any combination thereof. In some embodiments, the drug comprises GM-CSF, G-CSF, PDGF, BMP-2, bFGF, VEGF, SDF1, CXCL12, BMP-7, ghrelin, tocilizumab, anti-IL-5R, infliximab, etc., anti-TNFα, steroids, anakinra, IL-1RAntag, canakinumab, anti-IL1β, ixekizumab, anti-IL17A, rituximab, anti-CD20, ocrelizumab, abatacept, belatacept, CTLA4-Ig, alefacept, LFA3-Ig, alemtuzumab, anti-CD52, ATG, natalizumab, anti-α4-integrin, ruxolitinib, tofacitinib, JAK inhibitors, resveratrol, clodronate, GW2580, BLZ945, NPFF, cilostazol, pirfenidone, zafirlukast, aspirin, apremilast, famotidine, cetirizine, cilostazol, zafirlukast, apremilast, aspirin or any combination thereof. The drug may be released from the membrane for at least 3 days, at least 4 days, at least 5 days, at least 6 days, at least 1 week, at least 2 weeks, at least 3 weeks, at least 1 month, at least 2 months, at least 3 months, at least 4 months, at least 5 months, or at least 6 months.
[0144]
[0150] Drug delivery can be achieved by one or more of coating, embedding and / or encapsulation of the drug on / in the membrane (e.g., electrospun polymer membrane). Drug coating can be achieved by incubating the drug with the membrane (e.g., electrospun polymer membrane). In some embodiments, the drug is incubated with the membrane after electrospinning. In some embodiments, at least one of the polarity, pH, ionic strength of the fiber and solvent can allow for drug adsorption. Drug embedding can be achieved by dissolving the drug in the polymer solution. Drug encapsulation can be achieved by dissolving the drug in the polymer solution through a heterogeneous process (e.g., coaxial or emulsion electrospinning of a two-phase system) during preparation of the polymer solution. In some embodiments, the drug is dissolved in the polymer solution prior to electrospinning.
[0145] Treatment of Disease
[0151] The membranes disclosed herein (e.g., electrospun polymer membranes), including the crosslinked functional membranes (e.g., electrospun polymer membranes) of the present disclosure, can be utilized to provide a therapeutic benefit to a subject in need thereof. The subject in need thereof can have a condition, such as a chronic disease. A chronic disease that can be treated with the membranes disclosed herein (e.g., electrospun polymer membranes) can include diabetes. The membranes (e.g., electrospun polymer membranes) can be implanted subcutaneously, into an organ parenchyma, into the peritoneal cavity, or intramuscularly in a subject.
[0146]
[0152] The subject in need thereof can be a human or a non-human primate. The subject in need thereof can also be other animals, including mice, rats, rabbits, and pigs. The membrane (e.g., electrospun polymer membrane) can be implanted into the subject in need thereof and designed to remain in the user for a period of time of more than 1 day, more than 2 days, more than 3 days, more than 4 days, more than 5 days, more than 6 days, more than 1 week, more than 2 weeks, more than 3 weeks, more than 1 month, more than 2 months, more than 3 months, more than 4 months, more than 5 months, or more than 6 months.
[0147]
[0153] The membranes (e.g. electrospun polymer membranes) disclosed herein can also be used for purposes other than implantation in subjects for therapeutic benefits.For example, these membranes can be used in filtration devices or handling materials, or as unloaded cell scaffolds on which cells can be seeded before implantation.Other applications can include subretinal implant supports, wound healing matrices, tissue culture supports, tissue fillers or dressings. EXAMPLES
[0148]
[0154] The invention is further illustrated by the following non-limiting examples. Example 1 Membrane production
[0155] This example describes the fabrication of a membrane (e.g., an electrospun polymer membrane). The membrane fabrication process was carried out using an environmentally controlled electrospinning apparatus (EC-CLI, IME Technologies) consisting of a single emitter with a 19-gauge needle spaced 5-17 cm from a rotating drum collector operating at 500 rpm with a diameter of 6 cm. The polymer solution (6% w / v) was passed through a 0.8 mm PTFE tube into the emitter at a flow rate of 16.7 μL / min at 23° C. with 50% humidity. The emitter was set to 15 kV-18 kV and the collection drum was held at -4 kV. After successful fiber formation, the x-axis translation stage of the emitter was set in a repeating linear pattern with a speed of 100 mm / s and a delay of 200 ms at the edges. The total collection time after activation of the translation stage was 140 min. Membranes (e.g., electrospun polymer membranes) can also be collected on patterned structures.
[0149]
[0156] The polymer solution includes a base polymer, a functional polymer, and / or a crosslinker. The base polymer includes PAN, PET, PLG, PHEMA, PCL, and / or PLLA. The functional polymer includes PEG, PEGMA, PEGDA, and / or TEGDA. The crosslinking initiator includes a photoinitiator, a thermal initiator, and / or a transition metal.
[0150] Example 2 PAN membranes of various diameters
[0157] This example describes scanning electron microscopy and cumulative release of protein from PAN membranes (e.g., electrospun polymer membranes) of various diameters. The membranes (e.g., electrospun polymer membranes) were prepared according to Example 1. PAN polymer was added to 6% (w / v) PAN polymer solution. The electrospinning was performed with a 50 μm thick polymer membrane with fibrous filaments of diameters of 540 nm, 325 nm and 202 nm, including the polymer solution concentration (w / v), positive and negative voltage settings (kV), feed rate, distance and time of electrospinning.
[0151] [Table 1]
[0152]
[0158] Electrospun polymer membranes were spun to a thickness of 50 μm. Electrospun membranes were coated with palladium-gold complex for visualization by scanning electron microscopy (SEM) at 8 kV. Release studies were performed using a Franz cell diffusion apparatus. Briefly, the membrane was mounted between two fluid chambers. FITC-dextran was used as a model drug, and phosphate-buffered saline (PBS) buffer was used as the release medium. Aliquots of the release medium were taken at various time points, and the diffused FITC-dextran was quantified based on the fluorescence intensity.
[0153]
[0159] FIG. 1 illustrates electrospun polymer membranes made from PAN-based polymers. FIG. 1A illustrates scanning electron microscopy (SEM) images of PAN-based polymers electrospun to obtain filaments of different diameters. The top row shows electrospun polymer membranes at 1500x magnification, and the bottom row shows electrospun polymer membranes at 5000x magnification. FIG. 1B illustrates the cumulative release over time of 4 kDa FITC-dextran molecules in electrospun polymer membranes with filament diameters of 540 nm, 325 nm, and 202 nm.
[0154]
[0160] SEM images show that fibers can be spun to obtain filaments of different diameters. As the filament diameter increases, the burst release of 4 kDa FITC-dextran molecules increases.
[0155] Example 3 Protein release from PAN electrospun polymer membranes
[0161] This example describes the release of proteins of different molecular weights from PAN electrospun polymer membranes. Electrospun polymer membranes were prepared according to Example 1. PAN polymer was electrospun in a 6% (w / v) polymer solution. Release testing was performed as described in Example 2 above.
[0156]
[0162] FIG. 2 illustrates the diffusion of 4 kDa FITC-dextran and 500 kDa FITC-dextran molecules from a base polymer blend electrospun to give a 540 nm or 202 nm filament diameter. FIG. 2A illustrates the diffusion of 4 kDa FITC-dextran and 500 kDa FITC-dextran molecules from a base polymer blend electrospun into a 100 micron thick membrane with 540 nm diameter filaments at 30 and 60 minutes. FIG. 2B illustrates the diffusion of 4 kDa FITC-dextran and 500 kDa X moieties from a base polymer blend electrospun into a 100 micron thick membrane with 202 nm diameter filaments at 30 and 60 minutes. The PAN electrospun membrane showed good selectivity of 4 kDa molecules over 500 kDa molecules in terms of flux. These membranes were permeable to 4 kDa FITC-dextran, but less permeable to 500 kDa FITC-dextran. FIG. 3 illustrates the diffusion coefficients of 4 kDa and 500 kDa moieties in various polymer membranes and the flux of the 4 kDa moiety in non-crosslinked and crosslinked electrospun polymer membranes of the present disclosure. FIG. 3A illustrates the diffusion coefficients of the 4 kDa and 500 kDa moieties in various polymer membranes and in non-crosslinked and crosslinked electrospun polymer membranes of the present disclosure. FIG. 3B illustrates the diffusion coefficients of the 4 kDa moieties in a polymer membrane compared to a Biopore ePTFE membrane according to an embodiment. FIG. 3B illustrates the diffusion coefficients of electrospun polymer membranes fabricated from poly(acrylonitrile) (PAN). In comparison to a commercially available membrane (Biopore ePTFE), the high-flux electrospun polymer membrane of this example shows particularly high flux of a 4 kDa protein while limiting the diffusion of a 150 kDa protein. FIG. 3B illustrates the flux of 4 kDa FITC-dextran in a range of uncrosslinked and crosslinked electrospun membranes synthesized using the methods described in Examples 1 and 2.
[0157] Example 4 Histological analysis of electrospun polymer membranes implanted in mice
[0163] This example describes the histological analysis of electrospun polymer membranes implanted in mice. PAN electrospun polymer membranes were prepared according to Example 1. PAN polymer was dissolved in 6% (w / v) polymer solution and electrospun as described in Example 2. Electrospun polymer membranes were implanted in the epididymal fat pads of NOD scid gamma (NSG) mice for 60 days. Mice were euthanized and tissues containing electrospun polymer membranes were autopsied, sectioned, and stained with hematoxylin and eosin (H&E).
[0158]
[0164] FIG. 4 illustrates photomicrographs of hematoxylin and eosin (H&E) stained tissue sections from mice implanted with cell-loaded PAN electrospun polymer membranes of the present disclosure into the epididymal fat pad. FIG. 4A illustrates the epididymal fat pad of a mouse implanted with a planar device structure from a cell-loaded electrospun polymer membrane. FIG. 4B illustrates the ingression of host cells into the wall of the electrospun polymer membrane after implantation into the epididymal fat pad of a mouse. These studies showed that cells encapsulated in the membrane can diffuse out of the polymer network. These results demonstrated that electrospun polymer membranes can be designed to allow cell migration. Electrospun polymer membranes can also be designed to prevent cell migration, for example, by crosslinking functional electrospun polymers.
[0159] Example 5 Mechanical strength of electrospun polymer membranes
[0165] This example describes the mechanical strength of electrospun polymer membranes. Electrospun polymer membranes were prepared according to Example 1. Various blends of ethylene carbonate:PAN and PAN:PEG were electrospun in 6% (w / v) polymer solution. Tensile properties were measured by stretching membrane strips of a given size in a controlled manner.
[0160]
[0166] FIG. 5 illustrates the test system used to measure the burst strength of planar devices fabricated from electrospun polymer membranes. FIG. 6 illustrates the burst analysis of various electrospun polymer membranes of the present disclosure. FIG. 6A illustrates the pressure (psi) at which an electrospun polymer membrane bursts for the following electrospun polymer membrane compositions: 1% ethylene carbonate:PAN, 1:1 PEG:PAN, 1:2.5 PEG:PAN, 1:5 PEG:PAN, and 1:10 PEG:PAN. FIG. 6B illustrates the maximum load (mN) measured according to ASTM D790-03 using a Flexion instrument that can be withstood by an electrospun polymer membrane for the following electrospun polymer membrane compositions: 1:1 PEG:PAN, 1:2.5 PEG:PAN, 1:5 PEG:PAN, and 1:10 PEG:PAN. Maximum load mechanical testing was performed using the ASTM D790 method. The 1:10 PEG:PAN electrospun polymer membrane withstood the highest burst pressure and highest maximum load compared to the 1% ethylene carbonate:PA membrane and the other PAN:PEG electrospun polymer membranes tested.
[0161] Example 6 Fabrication and testing of crosslinked functional electrospun polymer membranes
[0167] This example illustrates the preparation and testing of crosslinked functional electrospun polymer membranes of the present disclosure. The experiments are described below. Electrospun polymer membranes were fabricated according to Example 1. PEGMA:PAN polymers were electrospun in 6% (w / v) polymer solutions with ratios of 1:1 to 1:10 of PEGMA:PAN. Preparation of membranes for SEM and release testing is described above in Example 2. Separately, PAN:PEGMA polymers were electrospun in 6% (w / v) polymer solutions with 2% TEGDA. After collecting the electrospun polymer membranes, the membranes were irradiated under UV light to initiate crosslinking, resulting in crosslinked functional electrospun polymer membranes. UV exposure was performed using a UV crosslinker, which is a closed chamber with a UV lamp shining from above. The photoinitiator is present at a concentration of 1% and UV exposure is performed for 10 minutes.
[0162]
[0168] FIG. 7 illustrates a crosslinked functional electrospun polymer membrane of the present disclosure. FIG. 7A illustrates an SEM image of an uncrosslinked electrospun polymer membrane made of a 1:5 ratio of PEGMA (2 kDa):PAN (150 kDa). FIG. 7A shows the same electrospun membrane as in FIG. 7B but which had not been UV crosslinked. FIG. 7B illustrates an SEM image of a UV crosslinked electrospun polymer membrane made of a 1:5 ratio of PEGMA (2 kDa):PAN (150 kDa), where 2% TEGDA was introduced in the UV crosslinking step. The electrospun membrane was immersed in a solution of 2% TEGDA and the UV initiator dimethoxyacetophenone and exposed to UV light for crosslinking. FIG. 7C shows the cumulative release of 4 kDa FITC-dextran molecules over time from electrospun polymer membranes of the present disclosure including 1:10 PEGMA(2 kDa):PAN(150 kDa), 1:5 PEGMA(2 kDa):PAN(150 kDa), 1:10 PEGMA(2 kDa):PAN(150 kDa) with 2% TEGDA(0.3 kDa), and 1:10 PEGMA(2 kDa):PAN(150 kDa) with 2% TEGDA(0.3 kDa). SEM images confirmed the changes in the ultrastructure of the polymer network after crosslinking. For example, it was visually observed in the SEM images that the porosity was reduced after crosslinking. The release experiments showed that increasing the amount of PEGMA in the electrospun polymer membrane (1:10 PEGMA:PAN) attenuated the burst release of 4 kDa FITC-dextran molecules from the electrospun polymer membrane. Release experiments also showed that cross-linking of the electrospun polymer membrane further attenuated the burst release of 4 kDa FITC-dextran molecules from the electrospun polymer membrane.
[0163]
[0169] Attenuated total reflectance-FTIR (ATR-FTIR) was used with 32 scans. Figure 8 illustrates the crosslinking of the base polymer and functional polymer after electrospinning. Figure 8A illustrates that PEGMA itself can be UV crosslinked with a photoinitiator to provide a functional electrospun polymer membrane. Alternatively, PEGMA can be UV crosslinked with the crosslinker TEGDA to obtain a crosslinked functional electrospun polymer membrane. Figure 8B illustrates the Fourier transform infrared spectroscopy (FTIR) results showing the transition from C=C bonds to C-C bonds in the PEGMA polymer upon crosslinking. These results confirmed that chemical crosslinking occurs in the UV exposed crosslinked functional electrospun polymer membrane.
[0164]
[0170] Tensile strength and Young's modulus values were measured using an Instron Tensile using ASTM-882 02 Standard Test Method for Tensile Properties of Plastics. Release testing was performed as described above in Example 2. Figure 9 illustrates the tensile properties and permeability of crosslinked functional electrospun polymer membranes. Figure 9A illustrates the tensile strength (MPa) of 1:5 PEGMA(2kDa):PAN(150kDa) without TEGDA and 1:5 PEGMA(480Da):PAN(150kDa) with 2% (w / v) TEGDA and 1:5 PEGMA(480Da):PAN(150kDa) without TEGDA and 1:5 PEGMA(480Da):PAN(150kDa) with 2% (w / v) TEGDA. FIG. 9B shows 1:5 PEGMA(2 kDa):PAN(150 kDa) without TEGDA and 1:5 PEGMA(2 kDa):PAN(150 kDa) with 2% (w / v) TEGDA, as well as 1:5 PEGMA(480 Da):PAN(150 kDa) without TEGDA and 2% (w / v) TEGDA. Figure 9C illustrates the Young's modulus (MPa) of 1:5 PEGMA (480 Da):PAN (150 kDa) with 2% (w / v) TEGDA. Figure 9D illustrates the cumulative release of 4 kDa FITC-dextran molecules over time for various blends of 150 kDa PAN and 2 kDa or 480 Da PEGMA in crosslinked electrospun membranes with and without 2% (w / v) TEGDA.
[0165]
[0171] Tensile strength increased in functional electrospun polymer membranes crosslinked with TEGDA and was nearly the same for both 1:5 PAN(150kDa):PEGMA(2kDa) and 1:5 PAN(150kDa):PEGMA(480Da). Without the TEGDA crosslinker, the tensile strength of the PAN:PEGMA electrospun polymer membranes decreased as the molecular weight of PEGMA decreased. Young's modulus increased very slightly in functional electrospun polymer membranes crosslinked with TEGDA in 1:5 PAN(150kDa):PEGMA(2kDa), and Young's modulus increased significantly in functional electrospun polymer membranes crosslinked with TEGDA in 1:5 PAN(150kDa):PEGMA(480Da). Without the TEGDA crosslinker, the Young's modulus of the PAN:PEGMA electrospun polymer membranes decreased as the molecular weight of PEGMA decreased. Release experiments showed that inclusion of TEGDA crosslinker in crosslinked functional electrospun polymer membranes attenuated the release of 4 kDa FITC-dextran. Increasing the amount of PEGMA in electrospun polymer membranes without TEGDA increased the release of FITC-dextran. In functional electrospun polymer membranes crosslinked with TEGDA, decreasing the molecular weight of PEGMA attenuated the release of FITC-dextran.
[0166]
[0172] FIG. 10 illustrates SEM images showing the ultrastructure of functional electrospun polymer membranes after UV crosslinking without and with 2% (w / v) TEGDA. The electrospun polymer membranes were composed of 1:5 PEGMA (2 kDa):PAN (150 kDa) and 1:5 PEGMA (480 Da):PAN (150 kDa). The SEM images show the change in the overcoating after crosslinking in electrospun polymer membranes without TEGDA and with 2% TEGDA. Porosity was visually observed in the SEM images to be smaller in size for the membrane containing 480 Da PEGMA and crosslinked with 2% TEGDA.
[0167] Example 7 Insulin-secreting cell delivery in crosslinked functional electrospun polymer membranes
[0173] This example describes the delivery of insulin-secreting cells in a crosslinked functional electrospun polymer membrane. A membrane (e.g., an electrospun polymer membrane) is produced according to Example 1. A base polymer, a crosslinker, and a photoinitiator are electrospun using a technique to obtain a functional electrospun polymer membrane of suitable thickness. The base polymer includes PAN and PEGMA, the crosslinker includes TEGDA, and the photoinitiator includes dimethoxyacetophenone. The base polymer, the crosslinker, and the photoinitiator can be any of the polymers and compounds described herein. The functional electrospun polymer membrane is crosslinked with UV light to obtain a crosslinked functional electrospun polymer membrane. Cells are loaded into or seeded on the crosslinked functional electrospun polymer membrane, which is crosslinked by incorporation into the polymer solution prior to electrospinning. The cells are stem cells, e.g., stem cell-derived beta cells engineered to express insulin.
[0168] Example 8 Drug delivery in crosslinked functional electrospun polymer films
[0174] This example describes the delivery of a drug in a crosslinked functional electrospun polymer membrane. The electrospun polymer membrane is prepared according to Example 1. The base polymer, crosslinker and photoinitiator are electrospun using techniques to obtain a functional electrospun polymer membrane of suitable thickness. The electrospun polymer membrane is then field spun. The base polymer includes PAN and PEGMA, the crosslinker includes TEGDA, and the photoinitiator includes dimethoxyacetophenone. The base polymer, crosslinker, and photoinitiator can be any of the polymers and compounds described herein. The functional electrospun polymer membrane is crosslinked with UV light to obtain a crosslinked functional electrospun polymer membrane. Drugs are loaded into or seeded onto the crosslinked functional electrospun polymer membrane by incorporation into the polymer solution prior to electrospinning. Drugs include small molecules, such as hydrophobic or hydrophilic drugs, or biological materials, such as peptides or proteins. Particular drugs include immune response suppressants or oxygen generating agents.
[0169] Example 9 Diabetes Treatment
[0175] This example describes the treatment of diabetes in a subject in need thereof. Any crosslinked functional electrospun polymer membrane of the present disclosure is manufactured according to Example 1. Cells or drugs are loaded into the crosslinked functional electrospun polymer membrane as described in Examples 7 and 8. The cells are stem cell derived beta cells engineered to express insulin. The drug is insulin protein. These cell or drug loaded crosslinked functional electrospun polymer membranes are implanted into a subject in need thereof. The subject is any animal such as a mouse, rat, rabbit, non-human primate or human. The subject in need thereof has a disease. The disease is diabetes. Implanting the membrane improves the diabetic condition. The membrane manages the diabetic condition by releasing insulin for up to 6-36 months.
[0170] Example 10 Fabrication of electrospun polymer membranes with parallel filaments
[0176] This example describes the production of functional electrospun polymers with parallel filaments. The electrospun membrane fabrication process was carried out using an environmentally controlled electrospinning apparatus (EC-CLI, IME Technologies) consisting of a single emitter with a 19-gauge needle spaced 5-17 cm from a rotating drum collector operating at 500 rpm with a diameter of 6 cm. The polymer solution (6% w / v) was passed through a 0.8 mm PTFE tube into the emitter at a flow rate of 16.7 μL / min at 23 °C with 50% humidity. The emitter was set to 15 kV-18 kV and the collection drum was held at -4 kV. After successful fiber formation, the x-axis translation stage of the emitter was set in a repeating linear pattern with a speed of 100 mm / s and a delay of 200 ms at the edges. The total collection period after activation of the translation stage was 140 min. Electrospun polymer membranes can also be collected on patterned structures.
[0171]
[0177] The polymer solution includes a base polymer, a functional polymer, and / or a crosslinker. The base polymer includes PAN, PET, PLG, PHEMA, PCL, and / or PLLA. The functional polymer includes PEG, PEGMA, PEGDA, and / or TEGDA. The crosslinking initiator includes a photoinitiator, a thermal initiator, and / or a transition metal.
[0172]
[0178] Parallel filament formation will be ensured by measuring the angle of a representative sample of filaments in the electrospun membrane with reference to the y-axis orientation by scanning electron microscopy. This is performed on a sample size of at least 100 filaments at a magnification of 1,000x.
[0173] Example 11 Cell delivery in crosslinked functional electrospun polymer membranes
[0179] This example describes the delivery of cells in a crosslinked functional electrospun polymer membrane. The electrospun polymer membrane is manufactured according to Example 1. The base polymer, crosslinker and photoinitiator are electrospun using a technique to obtain a functional electrospun polymer membrane of suitable thickness. The base polymer includes PAN and PEGMA, the crosslinker includes TEGDA, and the photoinitiator includes dimethoxyacetophenone. The base polymer, crosslinker and photoinitiator can be any of the polymers and compounds described herein. The functional electrospun polymer membrane is crosslinked with UV light to obtain a crosslinked functional electrospun polymer membrane. Cells are loaded into or seeded on the crosslinked functional electrospun polymer membrane, which is crosslinked by incorporation into the polymer solution prior to electrospinning. The cells are parathyroid cells, retinal pigment epithelium or cardiomyocytes.
[0174] Example 12 Treatment of Ischemic Wounds
[0180] This example describes the treatment of ischemic wounds in a subject in need thereof. Any crosslinked functional electrospun polymer membrane of the present disclosure is manufactured according to Example 1. Cells or drugs are loaded into the crosslinked functional electrospun polymer membrane as described in Examples 7 and 8. The cells are engineered to express appropriate drugs for treating ischemic wounds, such as platelet derived growth factor (PDGF), connective tissue growth factor (CTGF), hepatocyte growth factor (HGF), stem cell factor (SCF), insulin-like growth factor (IGF-I), transforming growth factor beta-1 (TGF-B1), etc. These cell or drug loaded crosslinked functional electrospun polymer membranes are implanted into a subject in need thereof. The subject is any animal, such as a mouse, rat, rabbit, non-human primate, or human. The subject in need thereof has a disease. The disease is an ischemic wound. Upon implanting the membrane, the ischemic wound condition is improved.
[0175] Example 13 Treatment of Hypoparathyroidism
[0181] This example describes the treatment of hypoparathyroidism in a subject in need thereof. Any crosslinked functional electrospun polymer membrane of the present disclosure is manufactured according to Example 1. Cells or drugs are loaded into the crosslinked functional electrospun polymer membrane as described in Examples 7 and 8. The cells are engineered to express or secrete the appropriate drug, i.e., parathyroid hormone, to treat hypoparathyroidism. These cell- or drug-loaded crosslinked functional electrospun polymer membranes are implanted into a subject in need thereof. The subject is any animal, such as a mouse, rat, rabbit, non-human primate, or human. The subject in need thereof has a disease. The disease is hypoparathyroidism. Upon implantation of the membrane, the hypoparathyroidism condition is improved.
[0176]
[0182] While preferred embodiments of the present invention have been shown and described herein, it will be apparent to those skilled in the art that such embodiments are provided by way of example only. Numerous variations, changes and substitutions will now occur to those skilled in the art without departing from the invention. It should be understood that various alternatives to the embodiments of the invention described herein can be utilized in the practice of the invention. It is intended that the following claims define the scope of the invention and that methods and structures within the scope of these claims and their equivalents be covered thereby. This specification includes the following disclosure of the invention. [1] A device comprising a membrane and a population of non-native pancreatic beta cells, wherein the non-native pancreatic β cells exhibit an in vitro glucose-stimulated insulin secretion (GSIS) response to a glucose load; Here, the membrane has a molecular weight of about 2 or more. [ka] Ratio, where D first is the first diffusion coefficient for the first molecule having the first molecular weight, D secondis a second diffusion coefficient for a second molecule having a second molecular weight, and wherein the ratio of said second molecular weight to said first molecular weight is about 10 or greater. [2] The device of [1], wherein the non-native pancreatic beta cells are encapsulated within the device. [3] The device of [1] or [2], wherein the non-native pancreatic beta cells do not express somatostatin, glucagon, or both. [4] A device according to any one of [1] to [3], wherein the device is designed to produce and release insulin when implanted into a subject. [5] The device according to any one of [1] to [4], wherein the non-native pancreatic beta cells are present in an amount of about 10 per μL of volume. 4 ~about 10 6 A device in which a cell is enclosed within said device. [6] The device according to any one of [1] to [5], wherein the membrane is designed to block the passage of the non-native pancreatic beta cells. [7] A device comprising a membrane and a population of cells, wherein at least one cell of the population of cells produces a first molecule comprising a first molecular weight, and at least one cell of the population of cells produces a second molecule comprising a second molecular weight; wherein the device is designed, when implanted into a subject, to release the first molecule at a first flux rate and the second molecule at a second flux rate; A device wherein said first flow rate is different from said second flow rate, and wherein the ratio of said first molecular weight to said second molecular weight is from about 1.0 to about 5.0. [8] The device described in [7], wherein the first molecule or the second molecule comprises a therapeutic agent. [9] The device according to [7] or [8], wherein the first molecule is insulin.
[10] The device according to any one of [7] to [9], wherein the second molecule is glucagon.
[11] The device according to
[10] , wherein the ratio of the first molecular weight to the second molecular weight is about 1.6.
[12] The device according to any one of [7] to [9], wherein the second molecule is somatostatin.
[13] The device according to
[12] , wherein the ratio of the first molecular weight to the second molecular weight is about 3.5.
[14] The device according to any one of [8] to
[13] , wherein the therapeutic agent is a hormone or an enzyme.
[15] The device according to
[14] , wherein the therapeutic agent is a hormone.
[16] The device according to
[15] , wherein the therapeutic agent is an amino acid-derived hormone, an eicosanoid, a peptide hormone or a steroid.
[17] The device according to
[15] or
[16] , wherein the therapeutic agent is selected from the group consisting of glucagon, growth hormone, insulin, pancreatic polypeptide, parathyroid hormone, somatostatin and glucocorticoids.
[18] The device according to
[14] , wherein the therapeutic agent is an enzyme.
[19] The device according to
[18] , wherein the therapeutic agent is a protease, a lipase, The device is an enzyme that is an enzyme that is an enzyme that is an enzyme, such as an enzyme that is ...
[20] The device according to
[18] or
[19] , wherein the therapeutic agent is selected from the group consisting of angiotensinogen, trypsinogen, chymotrypsinogen, pepsinogen, fibrinogen, procaspase, pacifastin, proelastase, prolipase and procarboxypolypeptidase.
[21] The device according to any one of [7] to
[20] , wherein the cells comprise hormone- or enzyme-secreting cells.
[22] The device according to any one of [7] to
[21] , wherein the cells comprise non-naturally occurring cells.
[23] The device according to any one of [7] to
[22] , wherein the cells comprise stem cell-derived islet cells.
[24] The device according to any one of [7] to
[23] , wherein the cells comprise non-native pancreatic beta cells.
[25] The device according to any one of [7] to
[24] , wherein the cells exhibit an in vitro glucose-stimulated insulin secretion (GSIS) response to glucose loading.
[26] The device according to any one of [7] to
[25] , wherein the cells are encapsulated within the device.
[27] The device according to any one of [7] to
[26] , wherein the cells do not express somatostatin, glucagon or both.
[28] A device according to any one of [7] to
[27] , wherein the device is designed to produce and release insulin when implanted into the subject.
[29] The device according to any one of [7] to
[28] , wherein the cells are about 10 per μL in volume. 4 ~about 10 6 A device in which a cell is enclosed within said device.
[30] A device according to any one of [7] to
[29] , wherein the membrane is designed to block the passage of the cells.
[31] A device comprising a membrane and a therapeutic agent, wherein said non-native pancreatic beta cells are encapsulated within said device; Here, the membrane has a molecular weight of about 2 or more. [ka] Ratio, where D first is the first diffusion coefficient for the first molecule having the first molecular weight, D second is a second diffusion coefficient for a second molecule having a second molecular weight, and wherein the ratio of said second molecular weight to said first molecular weight is about 10 or greater.
[32] The device according to
[31] , wherein the therapeutic agent is a prodrug.
[33] The device according to
[31] or
[32] , wherein the therapeutic agent is less than 10 kDa.
[34] The device according to any one of
[31] to
[33] , wherein the therapeutic agent is a small molecule.
[35] The device according to any one of
[31] to
[33] , wherein the therapeutic agent is a biological substance.
[36] The device according to
[35] , wherein the biological material is a peptide or a protein.
[37] The device according to any one of
[31] to
[36] , wherein the therapeutic agent is a hormone or an enzyme.
[38] The device according to
[37] , wherein the therapeutic agent is a hormone.
[39] The device according to
[38] , wherein the therapeutic agent is an amino acid-derived hormone, an eicosanoid, a peptide hormone or a steroid.
[40] The device according to
[38] or
[39] , wherein the therapeutic agent is selected from the group consisting of glucagon, growth hormone, insulin, pancreatic polypeptide, parathyroid hormone, somatostatin and glucocorticoids.
[41] The device according to
[37] , wherein the therapeutic agent is an enzyme.
[42] The device according to
[41] , wherein the therapeutic agent is a protease, lipase, amylase, phospholipase A2, lysophospholipase or cholesterol esterase.
[43] The device of
[41] or
[42] , wherein the therapeutic agent is selected from the group consisting of angiotensinogen, trypsinogen, chymotrypsinogen, pepsinogen, fibrinogen, procaspase, pacifastin, proelastase, prolipase and procarboxypolypeptidase.
[44] The device according to any one of
[31] to
[43] , wherein the therapeutic agent is present in an amount ranging from about 0.01 mg therapeutic agent / mg polymer to about 0.5 mg therapeutic agent / mg polymer.
[45] A device according to any one of
[31] to
[44] , wherein the therapeutic agent is designed to be released from the membrane for at least three days.
[46] The device according to any one of
[31] to
[45] , wherein the therapeutic agent is hydrophobic.
[47] The device according to any one of
[31] to
[45] , wherein the therapeutic agent is hydrophilic.
[48] The device according to any one of
[31] to
[47] , wherein the therapeutic agent is in the form of finely divided particles.
[49] A device comprising a membrane, wherein the membrane comprises a polymer designed to allow encapsulation of a population of cells or a therapeutic agent in the membrane; wherein the membrane is: a) an average fiber diameter of about 1000 nm or less; b) average pore size of approximately 5 μm or less; c) an average thickness of less than about 500 μm; and wherein the membrane comprises at least one of about 2 [ka] Ratio, where D first is the first diffusion coefficient for the first molecule having the first molecular weight, D second is a second diffusion coefficient for a second molecule having a second molecular weight, and wherein the ratio of said second molecular weight to said first molecular weight is about 10 or greater.
[50] A device according to
[49] , wherein the polymer is designed to allow encapsulation of the population of cells.
[51] The device according to any one of
[49] to
[50] , wherein the cells comprise hormone- or enzyme-secreting cells.
[52] The device according to any one of
[49] to
[51] , wherein the cells secrete a therapeutic agent.
[53] The device according to
[52] , wherein the therapeutic agent is a hormone.
[54] The device according to
[53] , wherein the therapeutic agent is an amino acid-derived hormone, an eicosanoid, a peptide hormone or a steroid.
[55] The device according to
[53] or
[54] , wherein the therapeutic agent is selected from the group consisting of glucagon, growth hormone, insulin, pancreatic polypeptide, parathyroid hormone, somatostatin and glucocorticoids.
[56] The device according to
[52] , wherein the therapeutic agent is an enzyme.
[57] The device according to
[56] , wherein the therapeutic agent is a protease, lipase, amylase, phospholipase A2, lysophospholipase or cholesterol esterase.
[58] The device of
[56] or
[57] , wherein the therapeutic agent is selected from the group consisting of angiotensinogen, trypsinogen, chymotrypsinogen, pepsinogen, fibrinogen, procaspase, pacifastin, proelastase, prolipase and procarboxypolypeptidase.
[59] The device according to any one of
[49] to
[58] , wherein the cells comprise non-naturally occurring cells.
[60] The device according to any one of
[49] to
[59] , wherein the cells comprise stem cell-derived islet cells.
[61] The device according to any one of
[49] to
[60] , wherein the cells comprise non-native pancreatic beta cells.
[62] The device according to any one of
[49] to
[61] , wherein the cells exhibit an in vitro glucose-stimulated insulin secretion (GSIS) response to glucose loading.
[63] The device according to any one of
[49] to
[62] , wherein the cells are encapsulated within the device.
[64] The device according to any one of
[49] to
[63] , wherein the cells do not express somatostatin, glucagon or both.
[65] A device according to any one of
[49] to
[64] , wherein the device is designed to produce and release insulin when implanted into the subject.
[66] The device according to any one of
[49] to
[65] , wherein the cells are about 10 per μL in volume. 4 ~about 10 6 A device in which a cell is enclosed within said device.
[67] A device according to any one of
[49] to
[66] , wherein the membrane is designed to block the passage of the cells.
[68] A device according to any one of
[49] to
[67] , wherein the polymer is designed to enable encapsulation of the therapeutic agent.
[69] The device according to
[68] , wherein the therapeutic agent is a prodrug.
[70] The device according to
[68] or
[69] , wherein the therapeutic agent is less than 10 kDa.
[71] A device according to any one of
[68] to
[70] , wherein the therapeutic agent is a small molecule.
[72] The device according to any one of
[68] to
[70] , wherein the therapeutic agent is a biological substance.
[73] The device according to
[72] , wherein the biological material is a peptide or a protein.
[74] The device according to any one of
[72] to
[73] , wherein the therapeutic agent is a hormone or an enzyme.
[75] The device according to
[74] , wherein the therapeutic agent is a hormone.
[76] The device according to
[75] , wherein the therapeutic agent is an amino acid-derived hormone, an eicosanoid, a peptide hormone or a steroid.
[77] The device according to
[75] or
[76] , wherein the therapeutic agent is selected from the group consisting of glucagon, growth hormone, insulin, pancreatic polypeptide, parathyroid hormone, somatostatin and glucocorticoids.
[78] The device according to
[74] , wherein the therapeutic agent is an enzyme.
[79] The device of
[78] , wherein the therapeutic agent is a protease, lipase, amylase, phospholipase A2, lysophospholipase or cholesterol esterase.
[80] The device of
[78] or
[79] , wherein the therapeutic agent is selected from the group consisting of angiotensinogen, trypsinogen, chymotrypsinogen, pepsinogen, fibrinogen, procaspase, pacifastin, proelastase, prolipase and procarboxypolypeptidase.
[81] The device according to any one of
[68] to
[80] , wherein the therapeutic agent is present in an amount ranging from about 0.01 mg therapeutic agent / mg polymer to about 0.5 mg therapeutic agent / mg polymer.
[82] A device according to any one of
[68] to
[81] , wherein the therapeutic agent is designed to be released from the membrane for at least three days.
[83] The device according to any one of
[68] to
[82] , wherein the therapeutic agent is hydrophobic.
[84] The device according to any one of
[68] to
[82] , wherein the therapeutic agent is hydrophilic.
[85] The device according to any one of
[68] to
[84] , wherein the therapeutic agent is in the form of finely divided particles.
[86] The device according to any one of [1] to
[85] , wherein the membrane comprises an average fiber diameter of about 1000 nm or less.
[87] The device according to
[86] , wherein the average fiber diameter is about 800 nm or less.
[88] The device according to
[87] , wherein the average fiber diameter is about 500 nm or less.
[89] The device according to any one of [1] to
[88] , wherein the membrane comprises an average pore size of about 5 μm or less.
[90]
[89] The device according to claim 1, wherein the average pore size is about 2 μm or less.
[91]
[90] The device according to claim 1, wherein the average pore size is about 1 μm or less.
[92] The device according to any one of [1] to
[91] , wherein the membrane has an average thickness of about 800 μm or less.
[93] The device according to
[92] , wherein the average thickness is about 500 μm or less.
[94]
[93] The device according to claim 93, wherein the average thickness is about 200 μm or less.
[95] The device according to any one of [1] to
[94] , wherein the first molecular weight is less than about 10 kDa and the second molecular weight is greater than about 100 kDa.
[96] The device according to
[95] , wherein the first molecular weight is about 4 kDa and the second molecular weight is about 150 kDa.
[97] The device according to any one of [1] to [6] and
[31] to
[96] , wherein the first molecule is a 4 kDa FITC-dextran molecule, and the second molecule device, but a 500 kDa FITC-dextran molecule.
[98] The device according to any one of [1] to
[97] , wherein the membrane is an electrospun polymer membrane.
[99] The device according to any one of [1] to
[98] , wherein the membrane further comprises a base polymer.
[0100] The device according to
[99] , wherein the base polymer comprises PAN, PET, PLG, PHEMA, PCL or PLLA.
[0101]
[0100] A device according to the invention, wherein the base polymer is PAN.
[0102] A device according to any one of [1] to
[0101] , wherein the membrane further contains a functional polymer.
[0103] A device as described in
[0102] , wherein the functional polymer comprises PEG, PEGMA, PEGDA or TEGDA.
[0104]
[0103] A device according to the invention, wherein the functional polymer is PEGMA.
[0105]
[0103] A device according to the invention, wherein the functional polymer is TEGDA.
[0106] A device described in any one of
[0102] to
[0105] , wherein the functional polymer contains a reactive functional group.
[0107]
[0106] A device according to the present invention, wherein the reactive functional group is a carboxylate group, a hydroxyl group, an amide group, an azide group or a maleimide group.
[0108] A device described in any one of
[0102] to
[0107] , wherein the functional polymer has a molecular weight in the range of approximately 400 to 4000 Da. A device described in any one of
[0109]
[0102] to
[0107] , wherein the functional polymer has a molecular weight of approximately 480 Da. A device described in any one of
[0110] and
[0102] to
[0107] , wherein the functional polymer has a molecular weight in the range of approximately 1500 to 2500 Da. A device described in any one of
[0111]
[0102] to
[0107] , wherein the functional polymer has a molecular weight of approximately 2000 Da.
[0112] A device according to any one of [1] to
[0111] , wherein the ratio is about 3 or more.
[0113] A device described in any one of [1] to
[0112] , wherein the ratio is about 5 or more.
[0114] A device described in any one of [1] to
[0113] , wherein the ratio is about 10 or more.
[0115] A device according to any one of [1] to
[0114] , wherein the membrane has a tensile strength of about 1 MPa or more.
[0116] A device according to any one of [1] to
[0115] , wherein the film has a Young's modulus of about 5 MPa or more.
[0117] A device according to any one of [1] to
[0116] , wherein the membrane is hydrophilic.
[0118] A device according to any one of [1] to
[0116] , wherein the membrane is hydrophobic. A method for treating a disease comprising the steps of:
[0118] placing the device according to any one of [1] to
[0118] in a subject in need thereof; The method includes:
[0120]
[0119] A method as described above, wherein the device is designed to remain in the subject for a period of more than six months.
[0121]
[0119] or
[0120] , wherein the disease is a chronic disease. How to be a patient.
[0122]
[0121] A method according to the above, wherein the chronic disease is diabetes. A method according to any of
[0123]
[0119] to
[0122] , wherein the method further comprises monitoring the subject's insulin levels over the period of time longer than six months.
[0124] A method of making a device for delivering a population of cells or a therapeutic agent to a subject in need thereof, comprising the steps of: dissolving a polymer in a solvent to provide a polymer solution; forming a membrane containing fibers using the polymer solution; and Assembling said membrane into said device; wherein the device is a device described in any one of [1] to
[0118] .
[0125]
[0124] A method as described in claim 1, further comprising crosslinking the membrane.
[0126]
[0125] A method according to any one of claims 1 to 4, wherein crosslinking the film comprises exposing the film to ultraviolet (UV) light in the presence of a photoinitiator.
[0127]
[0126] The method according to any one of the preceding claims, wherein the photoinitiator is acetophenone, anisoin, anthraquinone, benzil, benzoin, benzenetricarbonylchromium, benzoin ethyl ether, benzoin isobutyl ether, benzoin methyl ether, benzophenone, 3,3',4,4'-benzophenonetetracarboxylic dianhydride, 4-benzoylbiphenyl, 2-benzyl-2-(dimethylamino)-4'-morpholinobutyrophenone, 4, 4'-Bis(diethylamino)benzophenone, camphorquinone, 2-chlorothioxanthen-9-one, (cumene)cyclopentadienyl iron(II) hexafluorophosphate, dibenzosuberenone, 2,2-diethoxyacetophenone, 4,4'-dihydroxybenzophenone, 2,2-dimethoxy-2-phenylacetophenone, 4-(dimethylamino)benzophenone, 4,4'-dimethylbenzyl, 2,5-dimethylbenzophenone (2,5-dime thylbenzonphenone, 3,4-dimethylbenzophenone, diphenyl(2,4,6-trimethylbenzoyl)phosphine oxide, 4'-ethoxyacetophenone, 2-ethylanthraquinone, ferrocene, 3-hydroxyacetophenone, 4-hydroxyacetophenone, 1-hydroxycyclohexyl phenyl ketone, 2-hydroxy-2-methylpropiophenone, 2-methylbenzophenone, 3-methylbenzophenone, methylbenzoyl formate, 2-methyl-4'-(methylthio)-2-morpholinopropiophenone, phenanthrenequinone, 4'-phenoxyacetophenone, thioxanthen-9-one, triarylsulfonium, hexafluoroantimonate salts, triarylsulfonium hexafluorophosphate salts, or any combination thereof. A method according to any one of
[0128]
[0125] to
[0127] , wherein crosslinking the membrane comprises exposing the membrane to heat in the presence of a thermal initiator.
[0129]
[0128] The method according to claim 1, wherein the thermal initiator is selected from the group consisting of ammonium persulfate, tert-amyl peroxybenzoate, 4,4-azobis(4-cyanovaleric acid), 1,1'-azobis(cyclohexanecarbonitrile), 2,2'-azobisisobutyronitrile, benzoyl peroxide, 2,2'-bis(tert-butylperoxy)butane, 1,1-bis(tert-butylperoxy)cyclohexane, 2,5 -Bis(tert-butylperoxy)-2,5-dimethylhexane, 2,5-bis(tert-butylperoxy)-2,5-dimethyl-3-hexyne, bis(1-(tert-butylperoxy)-1-methylethyl)benzene, 1,1-bis(tert-butylperoxy)-3,3,5-trimethylcyclohexane, tert-butyl hydroperoxide, tert-butyl peracetate, tert-butyl peroxide, tert-butyl peroxybenzoate, tert-butyl peroxy Methods including oxyisopropyl carbonate, cumene, hydroperoxide, cyclohexanone peroxide, dicumyl peroxide, lauroyl peroxide, 2,4-pentanedione peroxide, peracetic acid, potassium persulfate or any combination thereof. A method according to any one of
[0130] and
[0125] to
[0129] , wherein crosslinking the film comprises exposing the film to a transition metal.
[0131]
[0130] The method according to claim 1, wherein the transition metal comprises ions of beryllium, magnesium, calcium, barium, manganese, copper, iron or any combination thereof. A method according to any one of
[0132] and
[0125] to
[0131] , wherein crosslinking the membrane further comprises exposing the membrane to a crosslinking agent.
[0133]
[0132] The method according to the above, wherein the compound is selected from the group consisting of tetra(ethylene glycol) diacrylate, polyethylene glycol diacrylate, and the like. diacralte), bis(2-(succinimidyl-oxycarbonyloxyl)ethyl)sulfone, di(n-succinimidyl)glutarate, disuccinimidyl tartrate, 3,3'-dithiobis(sulfosuccinimidyl)propionate, p-phenylenediisothiocyanate, sebacic acid bis(N-succinimidyl)ester, suberic acid bis(N-hydroxysuccinimide ester), APN-CHO, bromoacetic acid N-hydroxysuccinimide ester, CBTF, iodoacetic acid N-hydroxysuccinimide ester, maleimido-PEG-succinimidyl ester, maleimido-acetic acid N-hydroxysuccinimide ester, adipic acid dihydrazide, alkyne-PEG-maleimide, APN-amine, APN-azide, APN-BCN, APN-COCl, biotin-benzyl-tetrate radish, biotin-PEG-TPG, 1,11-diazido-3,6,9-trioxaundecane, dibenzocyclooctyne-N-hydroxysuccinimidyl ester, dibenzocyclooctyne-maleimide, dibenzocyclooctyne-PEG-maleimide, 4-(maleimido)phenylisocyanate (approximately 95% pure), 4,4'-methylenebis(phenylisocyanate), 3-(2-pyridyldithio)propionylhydrazide, propargyl-N-hydroxylsuccinimidyl ester, PTAD-azide, sulfo-NHS-diazirine, sulfosuccinimidyl 4,4'-azipentanoate, 4-(N-maleimido)benzophenone, 4-azidophenacyl bromide, 5-azido-2-nitrobenzoic acid N-hydroxysuccinimidyl ester acid N-hydroxy succinimide ester), succinimidyl-[4-(psoralen-8-yloxy)]butyrate, 4-benzoylbenzoic acid N-succinimidyl ester, 1,4-bis[3-(2-pyridyldithio)propionamido]butane, bis-maleimidoethane, dithio-bis-maleimidoethane, or any combination thereof.
[0134]
[0124] to
[0133] , the method further comprising adding a drug to the polymer solution.
[0135]
[0124] to
[0134] , wherein the solvent is a miscible solvent. A method according to any one of
[0136] ,
[0134] and
[0135] , wherein the drug is a hydrophobic drug. A method according to any one of
[0137] ,
[0134] and
[0135] , wherein the drug is a hydrophilic drug. A method according to any one of
[0138]
[0134] to
[0137] , wherein the drug is in the form of finely divided particles.
[0139] A method according to any one of
[0124] to
[0138] , further comprising encapsulating cells within the device.
[0140] A method according to any one of
[0124] to
[0139] , wherein the cell is a non-natural cell.
[0141]
[0124] -
[0140] The method according to any one of the above, wherein the cell is The method is a stem cell derived islet cell. A method according to any one of
[0142]
[0124] to
[0141] , wherein the cells exhibit an in vitro glucose-stimulated insulin secretion (GSIS) response to glucose loading. A method according to any one of
[0143] and
[0124] to
[0142] , further comprising collecting the fibers using a rotating drum collector.
[0144]
[0124] to
[0143] , further comprising collecting the fibers on a patterned structure.
[0145]
[0144] A method according to the above, wherein the film comprises the shape of the patterned structure. A method according to any one of
[0146] and
[0124] to
[0145] , wherein the solvent comprises DMF, acetone, acetonitrile, aniline, n-butyl acetate, cyclohexanone, chloroform, diacetone alcohol, di(ethylene glycol), dimethyl sulfoxide, dichloromethane, ethanol, ethyl acetate, ethylene dichloride, formic acid, glycerol, methanol, methyl acetate, morpholine, 2-nitropropane, 1-pentanol, n-propanol, pyridine, trifluoroethanol, tetrahydrofuran, water, or any combination thereof. A method according to any one of
[0147] and
[0124] to
[0146] , wherein dissolving the polymer in the solvent comprises dissolving a base polymer and a functional polymer in the solvent.
[0148]
[0147] A method according to the above, comprising dissolving the base polymer and the functional polymer in the solvent in a ratio of about 1:1 (w / w) or less.
[0149]
[0148] A method according to the above, comprising dissolving the base polymer and the functional polymer in the solvent in a ratio of about 1:5 (w / w) or less.
[0150]
[0149] A method according to the invention, comprising dissolving the base polymer and the functional polymer in the solvent in a ratio of about 1:10 (w / w) or less.
[0151]
[0150] A method according to the above, comprising dissolving the base polymer and the functional polymer in the solvent in a ratio of about 1:20 (w / w) or less.
[0152]
[0147] to
[0151] , wherein the base polymer and the functional polymer are present together with the solvent at about 6% by weight to volume percent. A method according to any one of
[0153] and
[0124] to
[0152] , wherein the membrane does not include a coating.
Claims
1. 1. An implantable device, comprising: a porous polymeric membrane comprising: an average pore size of 10 nM or more and 10 μm or less; Average thickness of 500 μm or less; A Young's modulus of at least 5 MPa, A tensile strength of at least 1 MPa, and D between 2 and 50 first / D second where D first is the first diffusion coefficient for the first molecule, D second is the second diffusion coefficient for the second molecule, the first molecule being 4 kDa FITC-dextran and the second molecule being 500 kDa FITC-dextran; having the implantable device further comprises a population of insulin-secreting cells encapsulated in the implantable device; An implantable device in which a porous polymer membrane is designed to block the passage of a population of insulin-secreting cells.
2. 10. The implantable device of claim 1, wherein the porous polymer membrane has an average fiber diameter of 1000 nm or less.
3. 3. The implantable device of claim 2, wherein the average fiber diameter is 500 nm or less.
4. An implantable device according to any one of claims 1 to 3, having an average thickness of 200 µm or less.
5. An implantable device according to any one of claims 1 to 4, having an average thickness of at least 10 µm and at most 150 µm.
6. An implantable device according to any one of claims 1 to 5, having an average pore size of 5 µm or less.
7. An implantable device according to any one of claims 1 to 6, having an average pore size of 1 µm or less.
8. An implantable device according to any one of claims 1 to 7, having a Young's modulus of at least 60 MPa.
9. An implantable device according to any one of claims 1 to 8, wherein the porous polymer membrane is hydrophilic.
10. An implantable device according to any one of claims 1 to 9, wherein the porous polymer membrane is crosslinked.
11. 11. The implantable device of any one of claims 1 to 10, wherein the porous polymer membrane comprises polyacrylonitrile (PAN), polysulfone (PSf), polytetrafluoroethylene (PTFE), polyurethane (PU), polyvinylidene fluoride (PVDF), or a combination thereof.
12. The implantable device of any one of claims 1 to 11, wherein the porous polymer membrane comprises polytetrafluoroethylene (PTFE).
13. The implantable device of any one of claims 1 to 12, wherein the porous polymer membrane is an electrospun polymer membrane.
14. 14. An implantable device according to any one of claims 1 to 13, wherein the porous polymer membrane comprises a polymer having a molecular weight of 400 Da or more and 1,500,000 Da or less.
15. The insulin-secreting cell population was 10 per μL volume. 4 ~10 6 An implantable device according to any one of claims 1 to 14, wherein the amount of cells is encapsulated within the implantable device.
16. 16. The implantable device of any one of claims 1 to 15, wherein the population of insulin-secreting cells comprises at least one selected from the group of pancreatic progenitor cells, endocrine cells, alpha cells, delta cells, and beta cells.
17. The implantable device of any one of claims 1 to 16, wherein the population of insulin-secreting cells comprises non-native beta cells.
18. D first is 10 -7 cm 2 18. The implantable device of claim 1, wherein the .lambda. / second or more.
19. 19. The implantable device of any one of claims 1 to 18, wherein the population of insulin secreting cells does not express somatostatin, glucagon or both.
20. 20. An implantable device according to any one of claims 1 to 19, which is designed to remain in the subject for a period of greater than six months.
21. The implantable device of any one of claims 1 to 20, wherein the population of insulin-secreting cells is derived from human cells.
22. 22. The implantable device of any one of claims 1 to 21, wherein the population of insulin-secreting cells is encapsulated within a luminal volume of the implantable device.
23. A composition for use in the treatment of diabetes comprising an implantable device according to any one of claims 1 to 22.
